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Tag der mündlichen Prüfung: 24. November 2006
Die Untersuchungen zur vorliegenden Arbeit wurden auf Anregung von Herrn Prof. Dr.
G. Klebe am Institut für Pharmazeutische Chemie des Fachbereichs Pharmazie der Philipps-
Universität Marburg in der Zeit von Februar 2003 bis September 2006 durchgeführt.





1.1 Protein-Ligand Interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Scope of this thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
2 DEVELOPMENT, VALIDATION AND APPLICATION OF ADAPTED
PEOE CHARGES TO ESTIMATE PKA VALUES OF FUNCTIONAL
GROUPS IN PROTEIN-LIGAND COMPLEXES 4
2.1 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2.2 THEORY AND ALGORITHM . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2.1 The PEOE procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2.2 Performance of the original PEOE charges in PB calculations . . . . . 7
2.2.3 Adaptation of the PEOE procedure . . . . . . . . . . . . . . . . . . . 8
2.2.4 Testing against 80 small organic molecules . . . . . . . . . . . . . . . . 10
2.2.5 Ionized molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.2.6 Comparison to PARSE and CHARMM charges . . . . . . . . . . . . . 12
2.2.7 Protein pKa calculations . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.3 MATERIALS AND METHODS . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.3.1 Solvation free energies . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.3.2 pKa calculations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.3.3 X-ray structures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.4 RESULTS AND DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.4.1 pKa calculations of protein residues . . . . . . . . . . . . . . . . . . . 16
2.4.2 pKa calculations on two complexes of thrombin . . . . . . . . . . . . . 24
2.4.3 pKa calculations on a dihydrofolate reductase complex . . . . . . . . . 27
2.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
3 PROTONATION CHANGES UPON LIGAND BINDING TO TRYPSIN
AND THROMBIN: STRUCTURAL INTERPRETATION BASED ON
PKA CALCULATIONS AND ITC EXPERIMENTS 30
3.1 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.2 RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.2.1 Estimating the accuracy of calculated protonation changes . . . . . . 33
3.2.2 pKa Calculations on the complexes . . . . . . . . . . . . . . . . . . . . 35
3.3 DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.3.1 Influence of conformational variations . . . . . . . . . . . . . . . . . . 40
II Contents
3.3.2 pKa values of histidine residues . . . . . . . . . . . . . . . . . . . . . . 40
3.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.5 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
4 ATYPICAL PROTONATION STATES IN THE ACTIVE SITE OF HIV-1
PROTEASE: A COMPUTATIONAL STUDY 46
4.1 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
4.1.1 Setting of the dielectric constant and handling of coupled systems . . 48
4.2 MATERIALS AND METHODS . . . . . . . . . . . . . . . . . . . . . . . . . 49
4.3 RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4.3.1 Calculations on two apo structures . . . . . . . . . . . . . . . . . . . . 52
4.3.2 Calculations for the complexes . . . . . . . . . . . . . . . . . . . . . . 54
4.4 DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
4.5 CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
5 PROTONATION EFFECTS IN HUMAN ALDOSE REDUCTASE 68
5.1 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.2 RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.2.1 Calculations for five holo structures . . . . . . . . . . . . . . . . . . . 69
5.2.2 Calculations for compounds with carboxylic head groups . . . . . . . . 74
5.2.3 Calculations for compounds containing spiro-hydatoins . . . . . . . . . 74
5.3 DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
5.3.1 Holo structures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
5.3.2 Carboxylic head groups . . . . . . . . . . . . . . . . . . . . . . . . . . 79
5.3.3 Spiro-hydatoins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
5.4 CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
5.5 MATERIALS AND METHODS . . . . . . . . . . . . . . . . . . . . . . . . . 82
6 PDB2PQR AS A NEW TOOL FOR THE SETUP OF PKA CALCULA-
TIONS ON PROTEIN-LIGAND COMPLEXES 84
6.1 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
6.2 PDB2PQR PRINCIPLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
6.3 SCRIPTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
6.3.1 Substructure matching . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
6.3.2 pka lig tool . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
7 SUMMARY,ZUSAMMENFASSUNG 91
7.1 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91







Protein-ligand complexation involves the formation of intra-molecular interactions such as
hydrogen-bonds, aromatic stacking, salt bridges and hydrophobic complementarity. A large
variety of different computational approaches exist for modelling these processes, ranging
from ab initio, semi-empirical, classical mechanics to empirical methods. These methods
are capable of computing individual aspects of the binding process; e.g., calculating the free
energy of binding, simulating the reaction path for a substrate, examining the conforma-
tional flexibility, investigating the role of water, to mention only a few. One effect that these
methods usually neglect concerns the protonation change upon ligand binding. Possible ex-
planations for this deficiency are the high computational burden and the lack of experimental
data.
Protonation changes are omnipresent in the field of enzyme catalysis, because many cat-
alyzed processes involve an acid-base reaction. Hence, a thorough understanding of such
processes is of utmost importance being confronted with aspects of computational drug de-
sign such as ligand optimization, docking or molecular dynamics simulations. Protein X-ray
crystallography represents an experimental method heavily applied in all stages of drug dis-
covery, and we will use many such structures as reference points for our pKa calculations,
but most often their resolution is not sufficient to draw conclusions about protonation states.
One impressive example for the thermodynamic contributions arising from protonation
effects is pepstatin binding to plasmepsin II: it was experimentally shown that the proton
transfer involved contributes almost 40 % of the total binding free energy change [1]. The
following examples illustrate that atypical protonation states for active site residues are not
as rare as one might anticipate: lysozyme is a very well studied enzyme with a glutamic acid
having a pKa value of 6.2 [2]. In thioredoxin, an aspartic acid shows a highly shifted pKa
value of 7.4 [3]. The pKa values of two histidine residues in a protein tyrosine phosphatase
are 8.3 and 9.2, respectively [4]. For dehydratase and epimerase, the pKa values of central
tyrosine residues are 6.4 [5] and 6.1, respectively [6]. In acetoacetate decarboxylase, a central
lysine residue shows a pKa value of 6.0 [7]. In all these cases, the protonation pattern is
different in the binding pocket, and it is crucial to obtain such knowledge when setting up
a virtual screening or docking campaign, because the physicochemical properties of one key
residue might have changed remarkably.
2 1.2 Scope of this thesis
The experimental effort required to detect perturbed pKa values is rather high. Furthermore,
applicable methods such as NMR impose limits with respect to protein size (NMR) or the
reaction being catalyzed (kinetic measurements). One method which does not suffer from
these deficiencies is isothermal titration calorimetry (ITC). It represents an experimental
technique enabling a full thermodynamic characterization of the protein-ligand binding pro-
cess. Furthermore, it allows to detect the net protonation change upon ligand binding, but
no microscopic picture is obtained showing where the protonation changes actually occur.
Such a structural interpretation is of utmost importance, in order to perform a factorisation
of thE ITC data into enthalpic and entropic contributions with respect to certain residues
in the binding pocket. For this purpose, theoretical approaches based on available structural
data become attractive.
A calulation method with moderate computational demands is given by the Poisson-
Boltzmann (PB) theory, which is a continuum electrostatics procedure. In general, inter-
and intra-molecular electrostatic interactions are among the key factors determining the
functional properties and structural stability of proteins [8, 9, 10, 11, 12, 13, 14, 15] and
these interactions are directly related to charges of titratable groups, which in turn can have
modulated protonation states. There is strong evidence for this, e.g., the pH-dependence of
enzyme activity [16]. The ubiquitously present water molecules in proteins and protein-ligand
complexes are simulated as a dielectric sphere, and this is the continuum part in the PB
model.
1.2 Scope of this thesis
Several studies have proved the predictive power of PB calculations for an accurate pKa esti-
mation in proteins [17, 18, 19, 20, 21]. However, to the best of our knowledge, no large-scale
study of protonation states in protein-ligand complexes has been performed. One reason
might be the lack of a generally applicable charge assignment procedure that works reliably
with both, proteins and small organic molecules based on a consistent approach. In the first
chapter of this thesis, we describe the development of such a charge model and its validation.
In the following chapters, three application studies for protein-ligand complexes with atypical
protonation states are described. For the serine proteases trypsin and thrombin and human
aldose reductase, in house and public ITC data are available, which reveal protonation
changes upon ligand binding [22, 23]. For the human immunodeficiency virus 1 protease,
NMR and kinetic measurements [24, 25, 26] detected perturbed pKa values of the catalytic
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dyad for the complexed and uncomplexed state of this enzyme.
In the last chapter, we outline our efforts towards an open source PDB2PQR program
[27] for a facilitated setup of pKa calculations on protein-ligand complexes. It includes a
substructure search for the ligand based on a small molecule database with experimentally
determined pKa values.
4 2.1 INTRODUCTION
2 DEVELOPMENT, VALIDATION AND
APPLICATION OF ADAPTED PEOE




The first (purely theoretical, because no protein x-ray structures were available at that
time) approach towards the handling of electrostatics in macromolecules was introduced by
Linderstrom-Lang[28]. In their model, the charges (within a protein) are assumed to be
spread uniformly over the surface of a spherical model. Three decades later, Tanford and
Kirkwood presented an improved model in which they consider Coulombic interactions be-
tween the charges[29]; this model was further enhanced (obtaining a good fit to experimental
data) by placing all charges onto the surface of the protein [30]. A consistent microscopic
treatment of the dielectric effect in proteins based on the protein dipole Langevin dipole
(PDLD) method was introduced by Warshel et al. [31][10][11][32]. Warshel also introduced
the microscopic free energy pertubation (FEP) [33] and the microscopic linear response
approximation (LRA) [32]. A (semi-macroscopic) combination of PDLD and LRA, called
PDLD/S-LRA, has been introduced [32][34]. Besides these microscopic and semi-macroscopic
electrostatic models, a wide range of different computational techniques has become available
for pKa calculations in proteins, including, for example, empirical models [35][36], simplified
electrostatic models using sigmoidally-screened Coulomb potentials [37], continuum electro-
static models such as Poisson-Boltzmann calculations [17]. Additionally, more sophisticated
methods such as pH-dependent MD simulations [38][39] or QM/MM approaches [40] have
been applied to protein pKa calculations. However, these approaches are computationally
rather demanding and hamper routine application to large protein data sets.
One popular method for pKa calculations in proteins is based on the Poisson-Boltzmann
(PB)[41] theory, which uses an implicit solvent model. Several investigations show the suit-
ability of the PB theory to estimate pKa values in proteins [17][42][43][18][19][20][21]. In a
PB calculation, the electrostatic potential of a solute molecule is calculated based on the
charge distribution of its atoms. Atomic partial charges are normally used to describe such
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charge distributions and they are, accordingly, key parameters in pKa calculations. Usually,
partial charges applied in force fields such as CHARMM [44], Amber [45], or OPLS [46] are
used for this purpose. Bashford et al. [47] analyzed the influence of different charge models
on pKa calculations and observed performance differences. Warshel studied the influence
that different charge models take in the PDLD method and they found that it is not crucial
[48]. Warshel and Chu also established a new charge model for pKa calculations within the
framework of the PDLD methodolgy and detected that the actual choice of the charges is
far less crucial than the choice/adjustment of the radii [49]. Sitkoff et al. developed an
optimized charge and radius set (PARSE) which is also often used for PB-based protein pKa
calculations [50]. However, only few studies have been developed which perform PB-based
pKa calculations on protein-ligand complexes [51][52]; the Åqvist group performed abso-
lute binding free energies calculations considering the effect of charged ligands on proteins
[53][54]. However, a systematic and large-scale study considering pKa shifts in protein-ligand
complexes is still missing. In part, this may be due to the lack of sufficient experimental
data to validate calculations on such systems; however, another possible explanation might
be that at present no routine is available to assign generic charges reliably to both, proteins
and small organic molecules, in one consistent approach.
Many different computational techniques can be used for assigning partial charges. They
range from empirical to semi-empirical [55], including RESP methods (Restrained Electro-
static Potential) [56], and differ significantly with respect to the required computational
resources. In the present contribution, a rather simple but generically applicable method
was chosen which is well-established in the drug-design field for large scale charge assign-
ments in database studies of organic molecules: the PEOE procedure, originally developed
by Gasteiger and Marsili [57]. Another straightforward method for assigning charges based
on a linear combination of atomic orbitals has been introduced by Del Re [58]. The PEOE
procedure attributes initial charge values based on orbital electronegativities and redis-
tributes these initial assignments iteratively until convergence is achieved. Interestingly,
PEOE charges have not yet been used for PB-based pKa calculations. Therefore, we have
tested the PEOE charges for the simultaneous charge assignment of protein and ligand func-
tional groups. We re-parameterized them based on solvation free energies and developed an
adapted PEOE procedure to calculate modified charges. Their broad applicability is based
on the fact that only hybridization states of the atoms (as defined by the atom types) are
required. Along with the development of a procedure to compute modified PEOE charges,
pKa calculations on protein-ligand complexes can be performed in automated fashion for
large-scale application studies.
The present contribution is structured as follows: First, the PEOE procedure is intro-
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duced and its performance on proteinogenic functional groups is assessed. Subsequently,
the re-parameterization for the calculation of solvation free energies is presented, first based
on amino acid side chains and then expanded to a dataset of small organic molecules. A
modification of the method to handle charged residues is discussed in the following. Using
a data set of nine proteins with 132 residues of experimentally determined pKa values, the
novel PEOE procedure is then tested retrospectively for its predictive power to reproduce
pKa values of amino acid residues in proteins. Finally, three applications with respect to
protein-ligand complexes are presented.
2.2 THEORY AND ALGORITHM
2.2.1 The PEOE procedure
Electronegativity is a chemically intuitive model descriptor for the charge distribution in
covalent bonds. Mulliken [59] defined the electronegativity χ as the arithmetic mean of the





Hinze [60][61] expanded this concept and introduced the orbital electronegativity χv, i.e. the
electronegativity of a specific orbital in a given valence state. The orbital electronegativity
is dependent on the type of orbital along with its occupation (and hence the charge). The
difference of the orbital charge density of an atom in its unperturbed state and in a molecular
environment can be interpreted as partial atomic charge qiv residing on the orbital v of atom
Ai. Accordingly, a functional dependence of the orbital electronegativity and the charge
can be established. In their original work [57], Gasteiger and Marsili used a second-order
polynomial to express the dependence of the orbital electronegativity on the atomic charge
qi. In a more recent version it was replaced by a third-order polynomial:
χv = av + bvq + cvq
2 + dq3 (2.2)
The coefficients av to dv could be derived from valence-state ionization potentials and elec-
tron affinities, with the coefficient av being equal to the orbital electronegativity of the
uncharged state [60].
To calculate the charge distribution in molecules, Gasteiger and Marsili developed an it-
erative procedure corresponding to a ”partial equalization of orbital electronegativities”
(PEOE). The inductive effect is considered by allowing transfer of charge between two
bonded atoms and directly bonded neighbors proportional to the difference of their orbital
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electronegativities. Thus, PEOE distributes the charges rather locally. To avoid total equal-
ization of electronegativity, the effect of the electrostatic field generated upon charge transfer
is considered via a damping factor which is exponentially reduced from one iteration to the
next. After an initial charge transfer, the new charges are used to update the electroneg-
ativties according to equation 2. The new electronegativities are then applied in the next
iteration to redistribute the charges, which in turn serve to update the electronegativities
and so forth. Due to the form of the damping factor, rapid convergence is achieved and the
procedure is usually terminated after six iterations, making the entire approach very fast.
2.2.2 Performance of the original PEOE charges in PB calculations
To assess the quality of the original PEOE charges (computed with the PETRA program
[62]) for PB calculations, solvation free energies were calculated using model compounds for
the side chains of polar amino acids for which experimental values are available [63]. Sol-
vation free energies were computed by solving the PB equation, using the program MEAD
[64] with the settings described in section Materials and Methods. Sitkoff et al. have carried
out a similar study to derive optimized parameters (charges and radii) for the estimation of
solvation free energies (the PARSE parameters) [65].
Using the original PEOE charges, the calculated solvation free energies show a correla-
tion of r2 = 0.79 with the experimental values. PARSE parameters give a correlation of r2
=1.0 for the same data set [65]. In the calculations with the PEOE charges, the solvation free
energies are generally underestimated. This might result from the fact that PEOE charges
were parameterized on gas phase data. Thus, these do not take solvation effects into account.
Although the PEOE procedure yields good dipole moments for gas phase data, this dipole
moment seems to be too small for dealing with solvation effects.
Therefore, in a first instance, the PEOE charges were uniformly scaled by a factor of
1.4 to enhance the polarization in the molecule’s interior and to lower the shielding effects.
This factor was adjusted by a least-squares fit of the calculated to the experimentally given
solvation free energies. The RMSD (root mean square deviation) between calculated and
experimental free energy of solvation amounts to 2.23 kcal/mol, r2 = 0.82. Investigation of
the revealed partial charges and comparison with the PARSE charges showed that the values
of our computed partial charges for nitrogen and oxygen were significantly lower.
This observation led to a manual redistribution of the partial charges on oxygen and ni-
trogen atoms to achieve a comparable polarization as suggested by the PARSE charges. A
very good correlation of calculated vs. experimental values resulted in r2 = 0.99. However,
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Table 2.1: Values of coefficient a for the PEOE procedure by Gasteiger et al. [16] and modifications
of a in the new approach. In column 3, the original coefficients are listed. In columns 4 and 5,
the modifications from the sections ”Adaptation of the PEOE procedure” and ”Testing against
80 small organic molecules” are listed.
Atom SYBYL atom type aorig Changes on a Changes on a
H H 7.17 0 0
C C.3 7.98 0 0
C.2 8.79 -0.4 0.5
C.ar 7.98 0.5 0.55
C.1 10.39 0 0
N N.ar 12.87 0 -1.29
N.3 11.54 2.5 6
N.2 12.87 -0.1 0
N.pl3 12.87 2 0.5
N.am 12.87 2.2 3.5
N.1 15.68 0 0
O O.3 14.18 0 -3.1
O.OH 14.18 - 0.8
O.2 17.07 -2.2 -2.2
O.co2 17.07 0 -1.82
F F 14.66 0 0
Cl Cl 11 0 1
Br Br 10.08 0 0.8
I I 9.9 0 1
S S.3 10.14 0.12 0.12
the performed modifications have the disadvantage that rather arbitrary, purely result-
oriented group-dependent corrections are required, which contradicts our initial idea of
developing a generally applicable partial charge model. Therefore, the PEOE procedure was
re-implemented in order to perform extensive parameter studies.
2.2.3 Adaptation of the PEOE procedure
Modifications were performed exclusively with respect to parameter a (see equation 2). The
original coefficients a, b, c, and d were taken from the VEGA software [66]. The modulated
coefficients a are shown in Table 2.1. The orbital electronegativities assigned to different
valence states are expressed in terms of SYBYL atom types. A slight modification of the sp2
hybridized carbon atoms (scaling down 4% for C.2, scaling up 6% for C.ar) yielded better
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Table 2.2: Calculated and experimental solvation free energies for the polar amino acids in kcal/mol.
In the middle columns, the results with the charges from the section Adaptation of the PEOE
procedure shown (r2 = 0.94, RMSD = 0.84). In the right-most columns, the results with the
charges from the section Testing against 80 small organic molecules are shown (r2 = 0.99,
RMSD = 0.54).
AS model compound ∆Gexp ∆Gcalc ∆∆Gexp ∆Gcalc ∆∆Gexp
ARG N-Propylguanidine -10.92 -10.9 0.02 -9.85 1.07
ASN Acetamide -9.72 -9.44 0.28 -8.98 0.74
ASP Acetic acid -6.7 -7.02 -0.32 -6.57 0.13
CYS Methylthiol -1.24 -1.48 -0.24 -1.02 0.22
GLN Propionamide -9.42 -8.77 0.65 -8.5 0.92
GLU Propionic acid -6.47 -6.47 0 -6.04 0.43
HIS Methylimidazole -10.25 -10.45 -0.2 -10.81 -0.56
LYS N-Butylamine -4.38 -1.42 2.96 -3.67 0.71
MET Methylethylsufide -1.49 -1.18 0.31 -1.04 0.45
PHE Toluene -0.76 -1.13 -0.37 -0.54 0.22
SER Methanol -5.08 -4.82 0.26 -4.83 0.25
THR Ethanol -4.9 -4.68 0.22 -4.53 0.37
TRP Methylindole -5.91 -6.14 -0.23 -5.72 0.19
TYR p-Cresole -6.13 -6.09 0.04 -5.94 0.19
agreement with the experimental values. Most modifications were required for nitrogen atom
types. The SYBYL atom type notation provides several descriptions for a sp2 nitrogen atom.
The practical application showed that such multiplicity is required for an optimal description.
Another modification concerns the damping factor: It was modulated from its original value
of 0.5 to finally 0.778. Additionally, the scaling factor which was adjusted by a least-squares
fit, converged to 1.56. This combination provide the best correlation between experimental
and calculated solvation free energies for the amino acid model compounds. Subsequent to
the PEOE procedure, this correction factor is multiplied uniformly to all partial charges,
scaling them to larger absolute values.
The calculated solvation free energies of the polar amino acid side chains based on the
modified charges are shown in Table 2.2 in comparison to the experimentally derived val-
ues. Figure 2.1 depicts the deviation between computational prediction and experiment.
The adaptation of the PEOE charge assignment shows that through minor modifications of
the original parameter set a convincing correlation between calculated and experimentally
determined solvation free energies can be obtained. Using the original PEOE charges, the
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Figure 2.1: Calculated vs. experimental solvation free energies for the polar amino acids model compounds
with parameters from the section Adaptation of the PEOE procedure. The correlation coefficient
r2 is 0.94, the RMSD is 1.32. The outlier is N-butylamine.
correlation coefficient r2 is 0.79, whereas with the modified charge set r2 amounts to 0.94.
The applied modifications are purely heuristic. Testing was performed exclusively using
polar amino acids as model compounds. To assess the scope and limitations for broad scale
applications, 80 small organic molecules for which experimental solvation free energies have
been reported were selected and a further cycle of parameter optimization was performed.
2.2.4 Testing against 80 small organic molecules
A set of 80 small organic molecules similarly used by Viswanadhan et al. [67] was taken from
the GALAXY program [68]. The original data set consisting of 292 compounds was reduced
to 80 representative compounds to avoid unnecessary redundancies displayed by very similar
compounds.
Directly applying the modified PEOE parameter set described in section Adaptation of
the PEOE procedure resulted in solvation free energies for the 80 small organic molecules
which deviated significantly from the experimental reference values. Ethers and alcohols
were particularly poorly predicted. Accordingly, we decided to introduce the new atom type
O.OH, which corresponds to a hydroxyl sp3 oxygen, leaving atom type O.3 for all remaining
non-hydroxy sp3 oxygens. In addition, the solvation free energies of amines were also rather
inadequately predicted. These observations stimulated a further cycle of iterative optimiza-
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tion of the electronegativity parameter a. The newly assigned values for a are listed in Table
2.1, in comparison to the parameters obtained from the first optimization cycle (section Adap-
tation of the PEOE procedure). The most pronounced changes concerned the nitrogen atoms.
The calculated solvation free energies for the model compounds of the polar amino acids
with these newly derived a coefficients are listed in Table 2.2. Compared to the first cycle of
the PEOE procedure, r2 improves from 0.94 to 0.99 (cf. Table 2.2). The calculated solvation
free energies for the 80 small organic molecules reveal an RMSD of 1.57 and a correlation
































experimental solvation free energy [kcal/mol]
Figure 2.2: Calculated vs. experimental solvation free energies for the validation set with 80 small organic
molecules with parameters from the section Testing against 80 small organic molecules. The
correlation coefficient r2 is 0.78, the RMSD is 1.57.
2.2.5 Ionized molecules
All molecules considered in the data set so far were handled as neutral species. The amount of
experimental values for solvation free energies of ionized molecules is very limited. However,
ionized functional groups are ubiquitously present in proteins: the amino acids arginine,
aspartate, glutamate, lysine normally bear a formal charge under physiological conditions.
Furthermore, cysteine, histidine, and tyrosine can possess a formal charge due to an altered
protonation state.
Formal charges can be treated in our adapted version of the PEOE procedure; they are
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Table 2.3: Comparison of experimental and calculated solvation free energies of ionized molecules.
ionized corresponding experimental calculated
system amino acid value value
N-butylammonium Lysine -66.35 -87
Methylimidazolium Histidine -59.14 -61.85
Acetate ion Aspartate -82.42 -91.97
Propionate ion Glutamate -80.63 -90.51
redistributed over several atoms. A fraction of the formal charge is added in each iteration
cycle of the PEOE procedure to finally achieve the total charge. In each iteration cycle, the
added fraction amounts to the formal charge divided by the number of applied iteration cy-
cles (default is 6), accordingly, after completing all iteration cycles the full amount of formal
charges has been assigned. The assignment of formal charges has to be performed prior to
the application of the PEOE procedure. For titratable residues, the initially assigned formal
charges are as follows: +0.5 (His, both ring nitrogens), -0.5 (Asp and Glu, both carboxylic
oxygens), +1.0 (Lys, terminal nitrogen), -1.0 (Tyr, hydroxylic oxygen without proton). Cys
and Ser are considered as too basic.
Experimental solvation energies of the charged form of the amino acids were taken from
Smith [69], Table 2.3 shows a comparison of the experimental and calculated values. The
best estimate is achieved for the model compound imidazole. Both acidic model compounds,
aspartate and glutamate, and the model compound for lysine are predicted significantly
worse. However, it must be noted that a statistically robust analysis would require many
more data points. Furthermore, the reported experimental values (-60 to -80 kcal/mol) fall
into a different range compared to the experimental values found for the neutral species (+3
to -10 kcal/mol) which were exclusively used for parameterization.
2.2.6 Comparison to PARSE and CHARMM charges
The resulting PEOE PB charges for the most essential atoms of the protein titratable groups
are listed in Table 2.4. Directly comparing charge models is complicated by the fact that
charges are not a physical observable. They are assessed indirectly by reproducing properties
accessible by experiment, e.g. dipole moment, electrostatic potential, or solvation energy.
PARSE charges [65] were optimized with the aim to reproduce solvation energies, but only
polar atoms bear charges unequal to 0, so that a direct comparison to our PEOE PB is diffi-
cult. Major deviations are observed for the backbone carbonyl group, where our PEOE PB
charges adopt smaller absolute values than in the CHARMM and PARSE model. In contrast,
for the backbone NH group, our approach converges to larger absolute values. For Asp and
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Table 2.4: Comparison of the different charges which were used for the pKa calculations.
CHARMM PARSE PEOE PB
bb CO C 0.51 0.55 0.14
O -0.51 -0.55 -0.3
bb NH N -0.47 -0.4 -0.73
HN 0.31 0.4 0.49
Asp/Glu C 0.62 0.1 0.11
(charged) O -0.76 -0.55 -0.7
Lys N -0.3 -0.32 -0.64
(charged) H 0.3 0.33 0.56
His Nδ1 -0.51 -0.35 -0.33
(charged) Cδ2 0.19 0.14 -0.01
Cε1 0.32 0.14 -0.07
Nε2 -0.51 -0.35 -0.34
Hδ1 0.44 0.45 0.51
Hδ2 0.13 0.13 0.28
Hε1 0.18 0.13 0.33
Hε2 0.44 0.45 0.5
Tyr OH -0.54 -.49 -0.6
(neutral) HH 0.43 0.44 0.44
CZ 0.11 0.06 0
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Glu, the carboxylate oxygens are handled by similar charges, whereas the CHARMM model
assigns a more positive value to the carboxylate carbon. For Lys, our PEOE PB charge model
assigns larger absolute values, whereas for His and Tyr all three models agree moderately.
2.2.7 Protein pKa calculations
Since the pKa value of a titratable residue (with all other titratable sites fixed in their neutral







[∆Gs,p(A) − ∆s,p(AH)] (2.3)
This gives the intrinsic pKa value pK inta : It is composed of the model pKa value pK
mod
a , which
corresponds to the pKa value of the isolated residue in aqueous solution and the difference
of the free energies of transfer from aqueous solution (s) to the protein environment (p) for
the protonated (AH) as well as the deprotonated form (A): [∆Gs,p(A) − ∆s,p(AH)]. ∆Gs,p
is composed of two terms: the Born term, accounting for the desolvation energy, and the
background term, which considers the electrostatic interaction with the permanent partial
charges of the protein. For the calculation of the intrinsic pKa value, all titratable groups are
treated in their neutral state. kB is the Boltzmann constant, and T is the temperature. A
comprehensive summary of how to calculate the required free energies and other competitive
methods for pKa calculations, the reader is referred to Warshel’s recent review [34] and the
references therein.
The interaction with the titratable groups adopting all possible protonation states is evalu-
ated via the site-site interactions energy term. Approximations are required to compute this
term since for m titratable sites 2m possible interactions must be considered. Bashford [70]
developed the ”reduced site” approach: It neglects those groups in the calculation of site-site
interactions that are either very close to full deprotonation or full protonation. This method
will be used throughout all pKa calculations in this study. The finally calculated pKa value
for each titratable residue is the sum of its intrinsic pKa value and the corresponding site-site
interaction energy term.
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Table 2.5: Parameter settings for ∆Gsolv calculations with MEAD.
Parameter Value
Grid size 65x65x65Å
Grid spacing 0.25 Å
Temperature 300 K
Ionic strength 0.1 mol/l
εSolvent 80
εMolecule 2
Table 2.6: Parameter settings for pKa calculations with MEAD.
Parameter Value
Temperature 300.0 K





Grid margin 20 Å
2.3 MATERIALS AND METHODS
2.3.1 Solvation free energies
A three-dimensional structure for all amino acid model compounds was generated using the
program CORINA [71] and minimized with the program MOE [72]. MEAD [64] was used
for the calculation of ∆Gsolv, with the settings listed in Table 2.5. The surface term was
calculated by MSMS [73], using Bondi’s radii [74]. The validation set of 80 small organic
molecules was taken from Viswanadhan et al. [67]; 3D coordinates were generated using
CORINA [71] and further applied without additional minimization.
2.3.2 pKa calculations
MEAD was applied for all pKa calculations [64] with the parameter settings listed in Table
2.6. All water molecules in the crystal structures were removed prior to the pKa calculation.
Site-site interactions were treated by the MEAD reduced-site approximation [70]. If not
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otherwise stated, εProtein was set to 20. A grid spacing of 1.0 Å was applied; next to the
titratable groups a focussed grid of 0.25 Å was utilized. The program REDUCE [75] was used
for adding hydrogen atoms. The following residues were considered as titratable (model pKa
value in parentheses): aspartic acid (4.0), C-terminus (3.8), glutamic acid (4.4), histidine
(6.3; only Nε was titrated), lysine (10.4), N-terminus (7.5), and tyrosine (9.6). No explicit
hydrogens were set at the carboxylic functions of glutamate and aspartate. All titratable
residues of the nine proteins listed in the next section were considered for the pKa calculations.
To assign titratable residues in the napsagatran/thrombin complex, all groups within a
12 Å sphere around napsagatran were considered. The model pKa values of the carboxylic
functions of napsagatran and CRC220 were set to the experimentally determined values of
3.4 and 3.8, respectively [22].
2.3.3 X-ray structures
In total, nine proteins were used for testing. In the following, they are referred to by their
PDB codes: 1A2P (barnase), 4PTI (bovine pancreatic trypsin inhibitor), 3ICB (calbindin),
2LZT (lysozyme), 1PPF (turkey ovomucoid third domain), 1PGA (protein G), 3RN3 (ribonu-
clease A), 2RN2 (ribonuclease H), and 1XNB (xylanase). The test data set thus comprised
132 experimentally determined pKa values [37, 18] (cases where only upper or lower bounds
of the experimental pKa were given are not considered).
The structure of the napsagatran/thrombin complex was kindly provided by Roche, Basel.
The coordinates of the CRC220/thrombin complex were taken from Fokkens [76].
2.4 RESULTS AND DISCUSSION
2.4.1 pKa calculations of protein residues
The test set consists of 132 experimental pKa values from a total of nine (uncomplexed)
proteins: barnase, bovine pancreatic trypsin inhibitor, calbindin, hen egg white lysozyme,
turkey ovomucoid third domain, protein G, ribonuclease A, ribonuclease H, and xylanase.
This data set was previoulsy used by Nielsen et al. [20] and we will refer to their results for
comparison.
The calculated pKa values for all 132 residues show an overall RMSD of 0.88 with respect
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Table 2.7: The overall RMSD (calculated versus experimental pKa values) listed for the nine proteins
of the validation set.
protein number RMSD RMSD RMSD RMSD RMSD
of exp. values PEOE PB PARSE CHARMM reference [20] Null model
Lysozyme 19 0.77 1 0.91 0.83 1.02
BPTI 10 0.48 0.52 0.45 0.37 0.6
Ovomucoid 15 0.67 0.55 0.61 0.8 1.08
Protein G 13 0.88 0.77 0.86 0.87 0.62
Ribonuclease A 16 0.91 1.34 1.16 1.37 0.86
Ribonuclease H 25 0.8 1.11 1.08 1.18 0.89
Barnase 12 1.12 1.09 1.03 1.29 1.37
Calbindin 10 0.66 0.66 0.72 0.39 0.71
Xylanase 12 1.35 1.4 1.55 1.18 1.74
total 132 0.88 1.01 1.01 1.02 1.04



















His Asp Glu Tyr Lys
Figure 2.3: Comparison of calculated and experimental pKa values for the validation set consisting of nine
proteins. The overall RMSD is 0.88 log units.
for each protein is listed. Substitution of the newly adapted PEOE charges (PEOE PB) by
CHARMM22 [77] charges and the corresponding radii reveals a less satisfactory RMSD of
1.01, substitution by PARSE charges gives also a RMSD of 1.01. Using an optimized hydro-
gen bond network, Nielsen et al. achieved an RMSD of 1.02 [20] (cf. Table 2.7). Splitting
up the 132 experimentally determinded pKa values into the different residue types results in
18 2.4 RESULTS AND DISCUSSION
the following RMSDs: Asp (44 values, RMSD: 0.88), Glu (33 values, RMSD: 0.94), His (13
values, RMSD: 1.24), Lys (29 values, RMSD: 0.61), Tyr (13 values, RMSD: 0.95). The overall
RMSD only measures the overall quality of pKa calculations. However, the experimental
values of a large percentage of residues in the data set shows only slight deviations from the
actual model values: Among the 132 experimental pKa values, 62 residues deviate by less
than 0.5 pKa units from the model pKa value. Such values have to be faced with a null
model which assumes no pKa shifts for any titratable residue. Overall, such a model reveals
an RMSD of 1.04 (for all 132 residues with experimental pKa values).
A more indicative analysis can be achieved by comparing only those titratable residues
that deviate experimentally by more than one pKa unit with respect to the model pKa.
Overall, 37 residues obey this criterion, and the resulting RMSDl (l for large) with the
PEOE PB charges amounts to 1.04. By using an optimized hydrogen bond network, Nielsen
et al. obtain an RMSDl of 1.12 for these residues. Considering the null model, the RMSDl
is 1.78. The experimental pKas of 21 residues deviate even more than 1.5 log units from the
model pKa, as listed in Table 2.8. In this table, not the absolute pKa values are listed, but
the differences ∆(pKaexp-pKamod) for the deviation from experiment to the model pKa and
∆(pKacalc-pKamod) for the different charge sets. In Figure 2.4, a discriminative benchmark
which plots these differences is displayed - such a benchmark was suggested by Warshel et
al. [34]. Interestingly, some residues show large shifts away from the model compound in
the opposite direction of the solvation free energy contribution (∆Gsolv favours the neutral
state of a titratable residue in the protein). This indicates that factors other than solvation
free energy must be responsible for these shifts. As a structural analysis shows, in most
of the cases, these residues are involved in salt bridges. For a number of residues, the dif-
ference between ∆(pKaexp-pKamod) and ∆(pKacalc-pKamod) is larger than one pKa unit.
The pKa shift of Asp83 in xylanase is strongly influenced by a salt bridge to Arg136. A
similar explanation holds for Asp148 in ribonuclease H which is involved in a salt bridge to
Arg46. Tyr31 in turkey ovomucoid third domain forms a hydrogen bond to Asp27. Asp101
in barnase forms three hydrogen bonds to Thr105 (backbone amide and side chain hydroxyl)
and Tyr103 (backbone amide). Asp14 in ribonuclease A is involved in a network of three
hydrogen bonds (side chains of Ser16, Thr17, Tyr25). His149 in xylanase is discussed in the
subsequent paragraph. The overestimation of the pKa shifts of the mentioned residues could
possibly be circumvented by the usage of a higher dielectric constant for the charge-charge
interactions (εeff in PDLD/S terminology) compared to εProtein (as performed by Warshel
et al. 13), but this is not possible in our PB setup. Alternatively, a further optimization of
the PEOE PB charges with respect to the interaction energies could yield an improvement.
The same may hold for the other charge sets which show a similar trend in the calculated
pKa shifts (and contributions from the site-site interactions) as the calculations with the
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Table 2.8: Residues which show a pKa shift of more than 1.5 log units from the model pKa, listed as
∆(pKaexp-pKamod). The differences for ∆(pKacalc-pKamod) with the PEOE PB, PARSE and
CHARMM charges are also listed. Figure 2.4 shows the corresponding diagram.
PDB code residue ∆(pKaexp ∆(pKacalc ∆(pKaPARSE ∆(pKaCHARMM
-pKamod) -pKamod) -pKamod) -pKamod)
2LZT 7-GLU -1.8 -1.29 -1.72 -1.53
2LZT 35-GLU 1.7 -0.08 -0.29 -0.29
2LZT 53-TYR 2.5 2.17 1.92 1.97
2LZT 66-ASP -2 -1.11 -2.31 -2.22
3RN3 2-GLU -1.6 -1.85 -2.48 -2.68
3RN3 14-ASP -2 -2.46 -3.49 -3.28
1PPF 31-TYR 2.9 4.5 3.13 4.28
2RN2 10-ASP 1.52 1.42 1.35 2.04
2RN2 102-ASP -2 -1.48 -2.25 -2.57
2RN2 127-HIS 1.6 2 1.49 2.02
2RN2 148-ASP -2 -3.22 -4.58 -4.1
1A2P 54-ASP -1.8 -2.66 -2.7 -2.48
1A2P 73-GLU -2.3 -2.35 -2.48 -2.54
1A2P 93-ASP -2 -1.58 -2.81 -2.07
1A2P 101-ASP -2 -0.32 -2.48 -1.08
1XNB 11-ASP -1.5 -0.55 -1.17 -0.67
1XNB 83-ASP -2 -3.3 -3.54 -4.71
1XNB 101-ASP -2 -1.54 -2.63 -2.49
1XNB 149-HIS -4 -0.69 -0.89 -0.84
1XNB 172-GLU 2.3 -0.22 -0.73 -0.74
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Figure 2.4: Discriminative benchmark for the residues in Table VIII (according to Warshel’s discriminative
benchmark [34]). Residues deviating more than one pKa unit are discussed in the text.
PEOE PB charges.
The RMSD between experimental and calculated pKa values for all residues in Table 2.8 is
1.28; CHARMM charges give an RMSD of 1.29, while PARSE charges result in an RMSD of
1.37. Nielsen et al. obtain an RMSD of 1.38, the null model would give an RMSD of 2.15. It
is worthwile noting, however, that the only two residues for xwhich the calculated protonation
state at physiological pH differs significantly from experiment are Glu35 in lysozyme and
Glu172 in xylanase. These two residues will be discussed below.
Xylanase is the protein which shows the largest overall RMSD (1.35, cf. Table 2.7). Only
a limited number of residues is responsible for this deviation: the active site residues Glu78
and Glu172 (their titration behaviour will be explored in detail in a subsequent paragraph),
Asp83 with a calculated pKa of 0.7 (pKaexp = 2.0; pKacalc = -0.7 using CHARMM charges),
and His149 with a calculated pKa of 5.6 (pKaexp = 2.3; pKacalc = 5.5 using CHARMM
charges). The pKa shift of Asp83 can be explained by the formation of a buried ion pair
with Arg136. The reason for the lowered pKa value of the buried His149 (see also Table 2.8)
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Table 2.9: Influence of the orientation of the OH-group of Tyr80 on the pKa values of Glu78 and
Glu172. std corresponds to the standard hydrogen setting with the program REDUCE, rotated
corresponds to a change in the dihedral angle of the hydroxyl group of Tyr80 by 180◦. For
comparison, the results with CHARMM charges are also shown.
εProtein = 4 exp std rotated std rotated
PEOE PB PEOE PB CHARMM CHARMM
Glu78 4.6 8.2 5.4 7.2 3.8
Glu172 6.7 4.1 9.7 2.9 10.1
is a hydrogen bond to a water molecule in close proximity. Although the deviation (pKacalc
- pKaexp) of both, Asp83 and His149, exceeds one log unit, the predicted protonation state
at physiological pH based on the calculated pKa values yields the correct sign. The same
conclusion applies to the results obtained with CHARMM charges.
In continuum electrostatics calculations, the choice of the dielectric constant of the pro-
tein is crucial. For microscopic solvent simulations, where all interactions are considered
explicitly, the dielectric constant of the protein is set to 1. Replacing the explicit solvent
molecules by an implicit solvation model, the dielectric constant of the protein has to be
assigned a value greater than 1. There is no universal dielectric constant to be assigned
to proteins [15]. The standard definition of a dielectric constant would be the relationship
between dipole fluctuations and the dielectric constant [34]. King et al. were able to show
that the (macroscopic) dielectric constant depends locally on the protein region and that the
reaction field (which is the effect of the missing solvent around the given region) has to be
taken into account [78]. In general, εProtein is simply an empirical parameter that tries to
represent contributions not included explicitly in the model [32, 15], such as protein reor-
ganization [34]. Warshel concluded that the actual value of the dielectric constant entirely
depends on the model and assumptions used to define this constant [11]. An overview on
how optimally selected values for εProtein depend on the selected model (Born, TK, MTK,
PDLD/S, PDLD/S-LRA) is summarized in Warshel’s review from 2001 [34]. Antosiewicz et
al. [18] obtained best agreement (concerning the overall RMSD) with experiment when using
a dielectric constant of 20. Also in our present study, this value has been used throughout
all performed pKa calculations, if not stated otherwise. Antosiewicz et al. rationalize this
setting by the fact that a rather high dielectric constant compensates for conformational flex-
ibility which is not taken into account explicitly. It was argued that this statement does not
hold, since the actual choice of the dielectric constant of protein depends on the benchmark
used for validation; furthermore, a rather high dielectric constant is caused by the ambition
to calculate self-energies and charge-charge interactions with the same dielectric constant
[34]. Nevertheless, the selection of the dielectric constant is crucial and this entity has to be
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regarded in the present calculations as an additional adjustable parameter.
For two enzymes in the validation set, experimental pKa values have been determined
for active site residues. Such residues are of special interest, because they are directly in-
volved in ligand binding. However, their prediction is not trivial due to a high degree of
burial and/or strong electrostatic interactions. In addition, the prediction of such residues is
challenging, because the previously described overall RMSD (0.88 with PEOE PB charges)
mostly considers surface exposed residues with small pKa shifts and every model using a
large dielectric constant (for the charge-charge interaction) will be accurate enough [79].
These two examples will show how cruical the choice of the dielectric constant is.
In lysozyme, glutamic acid 35 shows a pKa value of 6.2. The other catalytic residue, aspartic
acid 52, exhibits an experimental pKa of 3.6. The spatial arrangement of these residues is
shown in Figure 2.5. Warshel et al. investigated the influence of different dielectric constants
Figure 2.5: Active site residues Glu35 (pKa=6.2) and Asp52 (pKa=3.6) of lysozyme.
for εProtein and εeff (for the charge-charge interactions) and obtained best agreement with
experiment for Glu35 when setting εeff = 80 and εProtein = 4. Their results suggest to use
rather large values for εeff [34]. Such a treatment is not possible with our protocol, but
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it can be realized in the PDLD/S-LRA methodology. The latter approach refrains from
using a rather artificially high dielectric constant of the protein. Nevertheless, the present
pKa calculations on lysozyme show that a simple adjustment of εProtein (no differentiation
between εeff and εP as done by Warshel [34]) is able to produce correct trends: When setting
εProtein to 4, the calculated pKa of Glu35 is 6.0 (with εProtein =20, pKa
calc = 4.3) and 3.4
for Asp52 (with εProtein=20, pKa
calc = 3.8). Substituting our PEOE PB by CHARMM
charges results in similar values: With εProtein = 4, the calculated pKa of Glu35 is 5.1 (with
εProtein=20, pKacalc = 4.1) and 2.8 for Asp52 (with εProtein=20, pKacalc = 3.4). The same
trends are observed for PARSE charges: With εProtein= 4, the calculated pKa of Glu35 is 5.1
(with εProtein=20, pKa
calc = 4.1) and 2.9 for Asp52 (with εProtein=20, pKa
calc = 3.3). As
mentioned, in these calculations the actual value of εProteincannot be really justified by phys-
ical reasons (e.g. a dielectric constant derived from changes in the average dipole moment
[34]), which is a known problem of the PB method. Based on an optimized hydrogen-bond
network, Nielsen et al. [20] obtained a pKa of 5.7 for Glu35 and 1.8 for Asp52. Antosiewicz
et al. [18] calculated a pKa of 5.9 for Glu35 and 2.8 for Asp52 (εProtein=4). Demchuk and
Wade [19] did not achieve satisfactory prediction of the pKa value of Glu35 (4.5; pKa for
Asp52: 3.0), although their model uses two dielectric constants for the protein which would
suggest a better spatial adaptation of the dielectric conditions.
In xylanase, the active site comprises two glutamic acid residues (Glu172 and Glu78), with
pKa values of 6.7 and 4.6 respectively. Figure 2.6 depicts the overall geometry of the active
site. The experimentally determined pKa values (especially of Glu78) are not well repro-
duced applying εProtein =20 (Glu172: pKa
calc=4.2; Glu78: pKacalc=5.3). When decreasing
εProtein to 4, the prediction becomes even worse, because a dramatic upward shift in pKa
results for Glu78. A similar trend is recognized using CHARMM charges (see Table 2.9).
Nielsen et al. [20] obtained a pKa of 5.0 for Glu172 and 3.3 for Glu78 (based on an optimized
hydrogen bond network). Calculations based on mutants for which experimental values are
also available [80] demonstrate the importance of the hydroxyl group of Tyr80 which is in
close proximity to both active site glutamic acids. Upon mutation of this residue to Phe,
the experimentally determined pKa value of Glu172, which is also shifted upwards, can be
reproduced: In the Y80F mutant, the experimental pKa values of Glu172 and Glu78 are 7.9
and 5.0, respectively; the calculations yield 7.9 (Glu172) and 5.3 (Glu78) with an εProtein=4.
By variation of the dihedral angle of the hydroxyl group in the wild type (rotating off from
the standard geometry suggested by the program REDUCE [75]), the computed pKa of
Glu172 experiences the expected upward shift (εProtein= 4). The same trend is suggested
using CHARMM charges (see Table 2.9). Increasing εProtein from 4 to 20 reveals results
that are in less satisfactory agreement with experiment. Obviously in the present case, the
usage of a rather low value for the dielectric constant permits better pKa prediction of the
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Figure 2.6: Rotation of the OH-group of Tyr80 (of xylanase) in steps of 60 degrees. The catalytically relevant
glutamates 78 and 172 are displayed as capped sticks.
active site residues. In summary, our PEOE PB charges yield quantitatively reliable pKa
predictions of comparable or even better quality to competitive PB calculations in literature,
thus justifying their application in continuum electrostatics calculations. As major advantage
compared to other methods, the PEOE protocol can be easily extended to ligands covering
a much broader range of functional groups compared to protein residues.
2.4.2 pKa calculations on two complexes of thrombin
Isothermal titration calorimetry (ITC) directly records the thermodynamic contributions of
ligand binding to a protein. If ITC experiments are performed in different buffers, it is possi-
ble to discover protonation changes upon ligand binding. However, no microscopic picture is
obtained where the protonation changes actually occur, because only the net changes in the
protonation inventory are recorded. Dullweber et al. [22] performed ITC measurements on
a series of serine protease complexes. Two examples from this study (one with an observed
overall change of protonation and the other without any change) are studied computationally
here and the PEOE PB charges are applied for pKa calculation.
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Napsagatran and CRC220 are inhibitors of the serine protease thrombin (the chemical











































Figure 2.7: Napsagatran (a) and CRC220 (b) - inhibitors of the serine protease thrombin. The studied
inhibitor of dihydrofolate reductase, Methotrexate (c).
groups that could be classified as potentially titratable. Nevertheless, ITC indicates that only
Napsagatran binding induces a change in protonation state. Figure 2.8 shows the complexes
between thrombin, napsagatran and CRC220. An overall protonation change of +0.9 moles
of protons is observed upon formation of the thrombin-napsagatran complex [22]; thus, the
dissolved protein-ligand complex captures 0.9 moles of protons from the buffer. To obtain a
first clue on possible changes in protonation, Dullweber et al. also measured the napsagatran
ethylester. Interestingly enough upon complex formation no change in protonation states
could be observed. This suggests on first glance that the carboxylic function of napsagatran
picks up the proton. More striking is the fact that CRC220 does not provoke such changes
even though it has a very similar carboxylic function. Both ligands exhibit similar pKa
values for this functional group. ITC indicates only overall changes but does not answer the
question where the proton actually goes to, thus pKa calculations are consulted to provide
an explanation.
pKa calculations were performed for uncomplexed thrombin and for the thrombin-inhibitor
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Figure 2.8: Thrombin in complex with napsagatran (a) and CRC220 (b) - the surface of His57 is colored in
orange.
complexes. The uncomplexed form was generated using the coordinates of the complex by
removing the ligand. This rather pragmatic strategy is born out of the desire to achieve
general applicability, such that a structure of the uncomplexed protein does not have to be
necessarily available to perform such calculations. Admittedly, thrombin is an easy case since
only minor conformational adaptations are generally observed upon ligand binding. Thus,
the uncomplexed structure is indeed not required in this case.
The pKa calculations (εProtein = 20) show a pKa shift of histidine 57: its pKa value switches
from 7.3 in the uncomplexed structure to 8.5 in the complex with napsagtran. This pKa
shift can be considered significant, recalling the range defined in section pKa calculations
of protein residues. Furthermore, an experimental value for the pKa of His57 has been
determined for the homologous serine proteases trypsin and chymotrpysin, and it was found
to be close to 7.0, well in agreement with our calculations for the uncomplexed thrombin.
No other residues of the protein show significant pKa shifts upon complex formation, nor
do functional groups of the ligand - the carboxylic group of napsagatran definitely remains
deprotonated.
Surprisingly, ITC reveals no change of protonation upon formation of the CRC220/thrombin
complex, even though very similar functional groups are involved. However, crystallography
has revealed a different binding mode with respect of the placement of the carboxylic group
in a different area of the binding site. It is pointing towards the adjacent solvent environ-
ment. The calculations with the new PEOE procedure show no significant pKa shifts of any
residues or ligand functional groups when comparing the complexed and uncomplexed form.
The pKa values for His57 move only slightly from 6.1 (uncomplexed) to 5.7 (complexed),
which results in no significant change of protonation. The carboxylic group of the CRC220
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also remains in its original protonation state (i.e., deprotonated). No other titratable residue
shows significant pKa shift which could lead to a change of protonation. Accordingly, the
calculations are in agreement with the ITC observations for the CRC220/Thrombin complex.
2.4.3 pKa calculations on a dihydrofolate reductase complex
DHFR (dihydrofolate reductase) belongs to the enzyme class of oxido-reductases. MTX
(methotrexate, for chemical formula see Figure 2.7c) is a small molecule inhibitor of DHFR
which resembles the structure of the natural substrate, folate. The binding of MTX to DHFR
is known to be strongly pH-dependent [81, 82].
Early binding studies suggested that Asp27 is protonated in the free enzyme with a pKa of
6.6 [82]. NMR studies [81, 83, 84] showed that in the DHFR/MTX complex, the N1 nitrogen
of the pteridine ring is protonated even at a pH greater than 10, although the pKa value in
solution is significantly lower (pKa=5.7). It is believed that Asp27 and the N1 nitrogen form
a salt bridge. As a result, Asp27 would be no longer protonated.
To study the crucial protonation states and the question of a potentially formed salt bridge,
pKa calculations with the PEOE PB charges were carried out, in similar fashion as described
by Cannon et al. [51]. Two calculations were performed for the crystal structure with the
PDB code 4DFR, since two independent molecules are present in the unit cell (referred to as
MTX-A and MTX-B), due to higher completeness the usage of MTX-B for PB calculations
was recommended by Cannon et al. [51].
The calculations (εProtein=20) for MTX-B show that a significant pKa shift occurs for
nitrogen N1 of MTX, namely from 5.7 (apo) to 7.6 (complexed). Asp27 shows a pKa shift in
the opposite direction, from 3.4 to 0.5. The same trend can be observed when using MTX-A
as model: The pKa of N1 shifts from 5.7 (apo) to 7.9 (complexed), and the pKa of Asp27
is lowered from 2.9 to 0.0. This result suggests the formation of a salt bridge between the
protonated N1 of MTX and the deprotonated Asp27 of DHFR. Our results are in disagree-
ment with the calculations of Cannon et al. [51], but correspond to the experimental results
[81, 82, 83, 84]. Cannon at al. applied the same methodology (PB-based pKa calculations),
but they used OPLS charges for the protein and ab initio charges (HF/3-21G) for the ligand.
The application of charges derived from quantum chemical calculations is one of Cannon’s
explanations for the failure of their pKa calculations [51]. With our adapted PEOE charges,
we are able to produce consistently charges using one computational method for both, protein
and ligand. Furthermore, the computational burden for the charge calculation (involving ab
initio methods) is reduced to a minimum, and the setup of the pKa calculations is simplified.
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Most important, our results are in agreement with experiment.
2.5 Conclusions
The adaptation of the well-established PEOE formalism [57] to charge calculations in aque-
ous phase and of proteins, as well as its application to compute solvation free energies and
pKa values in proteins is described in this contribution. Experimental solvation free energies
of small organic molecules are well reproduced (see section Testing against 80 small organic
molecules). The application of our adapted PEOE charges in pKa calculations shows con-
vincing agreement with experiment, and equally good or better results are obtained compared
to other PB-based studies [17][18][19][20] (see section pKa calculations of protein residues).
Even though a competitive approach, the PDLD/S-LRA method, yields more accurate re-
sults for lysozyme [34], the pKa values of enzyme active site residues are still satisfactorily
reproduced with our approach, suggesting the application of the method to pKa calculations
of active site residues and protein-ligand complexes. Good agreement with experiment could
be achieved for three protein-ligand complexes. As a major advantage compared to any other
presently known charge assignment procedure used for continuum electrostatic calculations
of macromolecular systems, the approach is parameterized for proteinogenic groups and a
broad range of organic molecules.
Many protein-ligand complexes are known to change protonation states upon ligand binding.
With the newly introduced charge model, we propose a simple protocol useful for perform-
ing pKa calculations on such complexes. This suggests incorporating such calculations in
early steps of drug design, in particular to assume correct protonation states of the residues
involved in ligand binding. For docking and scoring it is of utmost importance to consider
the binding site residues and the functional groups of the docked ligands with appropriate
protonation.
Furthermore, such calculations are an essential prerequisite to correctly interpret thermody-
namic measurements. The complex formation of the above-mentioned thrombin inhibitors
napsagatran, its ethylester and CRC220 has been studied by isothermal titration calorimetry
[22]. This method provides experimental access to the binding free energy ∆G and the
heat produced or absorbed during the binding process. After correction of all contributions
involving changes in protonation states, the latter entity allows estimating the enthalpy of
binding. By calculating the difference between ∆G and ∆H the entropic contribution to
binding (-T∆S) can be determined. Correct factorization of ∆G into enthalpy and entropy
provides important insight into the thermodynamic driving forces of binding. CRC220 and
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the ethylester of napsagatran bind to thrombin without change of protonation state. Ac-
cordingly, the recorded heat can be directly translated into ∆H and, subsequently, ∆G can
be factorized in ∆H and T∆S (see Dullweber et al. [22]). The situation is very different
for napsagatran. Here a proton is transferred and the present calculations suggest that the
proton is picked up by His57 and not, as originally assumed by Dullweber et al. [22], by the
carboxylic group of napsagatran. If a proton is transferred from the buffer, corrections for
the heat of ionization of the buffer functional group has to be performed. But this correction
covers only part of the superimposed heat contributions. Furthermore, the heat of ionization
of the group picking up the proton has to be corrected. At this point, it is very important
whether the proton goes - as originally assumed - to the carboxylic group of the inhibitor or
- as the calculations suggest - to the nitrogen atom of His57. This is simply due to the fact
that the heat of ionization of an oxygen functional group (e.g. COO−/COOH ≈ 1-2 kJ/mol)
[22] is much lower than that of nitrogen functional group (e.g. imidazole/imidazolium ≈
30 kJ/mol)(http://www.lsbu.ac.uk/biology/enztech/ph.html). Since the binding of napsaga-
tran involves the transfer of one proton, the difference in correction for either COO− or His57
as acceptor amounts to about 28 kJ/mol, which would suggest very different factorizations
of ∆G into ∆H and -T∆S. Deviating interpretations of the thermodynamic properties of
napsagatran binding will be the consequence. Perhaps the last example emphasizes the
utmost importance of pKa calculations and the correct assignment of protonation states for
the interpretation of ITC data, in particular considering that this method become more and
more popular in recent times.
SUPPLEMENTARY MATERIAL AVAILABLE
The adapted PEOE PB charges will be made available in a future release of the open source
project PDB2PQR [27].
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3 PROTONATION CHANGES UPON LIGAND
BINDING TO TRYPSIN AND THROMBIN:
STRUCTURAL INTERPRETATION BASED
ON PKA CALCULATIONS AND ITC
EXPERIMENTS
3.1 INTRODUCTION
The protein-ligand binding process is governed by several types of interactions, such as
hydrogen bonds, charge interactions, aromatic stacking, and hydrophobic complementarity.
One feature which is often neglected for the sake of simplicity is the change of protonation of
ligand and protein functional groups upon complex formation. Systematic studies considering
such protonation effects have been rarely performed due to their experimental complexity.
Isothermal titration calorimetry (ITC) represents one experimental method for the detection
of overall changes in protonation. However, ITC reveals only the net stoichiometry for the
exchange of protons and does not provide structural evidence which groups release or pick up
the protons being transferred. More detailed insights on the molecular level can be gained
computationally by calculating pKa values of functional groups and their changes upon
complex formation. Calculations based on the Poisson-Boltzmann (PB) have achieved con-
vincing agreement with experimental pKa values observed for protein residues [17, 18, 20, 21].
Other competitive approaches such as the protein-dipole Langevin-dipole method (PDLD)
[10, 11, 31, 32], empirical models based on rules for hydrogen-bonding contributions and sol-
vation effects [36, 35] or simplified electrostatic models using sigmoidally-screened Coulomb
potentials [37] have also shown convincing agreement with experimental data. We have
recently developed a generally applicable charge model to be used in PB-based pKa calcula-
tions of protein-ligand complexes [85]. The present contribution describes the application of
this method on trypsin and thrombin complexes (Figure REF), which have been experimen-
tally studied in our laboratory by ITC [22]. Evidence from the computational evaluations is
used to interpret and factorize experimental microcalorimetric data recorded for a series of
structurally related complexes.
Trypsin and thrombin belong to the family of trypsin-like serine proteases. They are well-
established model systems to study fundamental concepts of protein-ligand interactions.
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Figure 3.1: Trysin (colored pale yellow) and thrombin (colored green) in complex with the following ligands:
a) 1b (yellow) and 2 (white), b) 1c (yellow) and 1d (white), c) 2 (white) and 3 (yelow), d) 4 (yellow)
and 5 (white). The catalytic triad and Asp189 of the S1 pocket are shown in stick representation. The
figure was generated with PyMOL [86]
Both enzymes catalyze the peptide-bond cleavage by means of their active-site residues
His57, Asp102, and Ser195 which together compose the catalytic triad. Although the cat-
alyzed reaction is identical, trypsin and thrombin are parts of different biological pathways:
Trypsin is involved in digestion, whereas thrombin is engaged in the blood clotting cascade.
Thrombin has been a target of pharmaceutical relevance for a long time, since its inhibition
seems promising for the treatment of thrombosis via orally available drugs. However, such
drugs should be selective for thrombin avoiding undesired crossreactivity with the structurally
very similar trypsin. Therefore, the two proteins represent an ideal system to elucidate the
selectivity determining features. In Figure 3.1, the key characteristics of the binding pocket
of trypsin/thrombin are shown: The S1 pocket can accommodate a positively charged func-
tional group, normally forming a salt bridge to Asp189. Aromatic interactions are possible on
the residues flanking the S3 pocket. In thrombin, different to trypsin, the extended 60-loop is
present and closes the S2 pocket from the surrounding solvent environment. In both enzymes,
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Figure 3.2: Schematic representation of the trypsin/thrombin active site. The following color code is used
for the amino acids: green for trypsin, yellow for thrombin, grey for trypsin and thrombin. The 60s
loop is only present in thrombin.
adjacent to the catalytic triad the oxy-anion hole is found.
One prerequisite for endowing ligands with enhanced target selectivity by rational con-
cepts is the experimental factorization of affinity into entropic and enthalpic contributions,
e.g. by means of isothermal titration calorimetry (ITC). In addition, this method provides
indirectly the overall change in protonation when a ligand binds to a protein. In the present
study, we show results from a computational study which help to understand and interpret
unexpected protonation effects upon ligand binding to trypsin and thrombin. Such results
are essential for correctly factorizing ITC data, because the heat of ionization required for
this factorization depends on the titratable group. Only if this heat effect is appropriately
accounted for, a meaningful partitioning in ∆H and -∆TS can be performed.
In a previous communication, the experimental characterization of the thermodynamic and
structural properties for a series of protein-ligand complexes of trypsin and thrombin has
been described [22]. For one thrombin and three trypsin complexes, a change of protonation
has been detected during the ligand binding process (Table 3.1). However, ITC and X-ray
crystallography did not allow to unequivocally assign the proton donor or acceptor. This
assignment, which is crucial for the thermodynamic interpretation, will be the main subject
of this contribution.
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Table 3.1: Net change of protonation (measured by ITC) upon ligand binding to trypsin or thrombin [22]: a








The results of the pKa calculations will be discussed in light of the experimentally determined
protonation changes ∆nexp (a positive sign corresponds to a proton uptake from the buffer
upon complexation, whereas a negative sign symbolizes a release of protons); it is given
in moles of protons per mole titratable group. Only pKa shifts between the apo and the
complexed form which result in a protonation change will be described. Subsequently, the
corresponding degrees of protonation and the resulting change in protonation .ncalc upon
ligand binding will be portrayed based on the Henderson-Hasselbalch equation and a pH
of 7.8 as used in all ITC experiments. Besides the overall ∆ncalc, the protonation change
∆ncalc/HL (based solely on pKa shifts of His57 and the ligand) will be evaluated. All results
are summarized in Table 3.2.
3.2.1 Estimating the accuracy of calculated protonation changes
Before describing any individual results, we would like to point out some general concepts
of protonation states and their possible changes combined with an attempt to assess the
significance and accuracy of protonation-change calculations.
In the context of the present study, we aim at the prediction of protonation changes oc-
curring upon protein-ligand binding. Using a model screnario, we try to clarify what is a
significant pKa shift with respect to protonation changes. As an example, consider a titrat-
able group with a pKa of 7.0. In a solution of pH 7.0 (i.e, the same value as the pKa),
the group is 50 protonated. If in this group a pKa shift of one unit is induced (e.g., by
the ligand-binding process), the protonation changes by ± 41%, i.e. to 91% protonation if
a shift of +1 pKa unit is induced or to 9% protonation if the pKa is shifted by -1. This
essentially results in a fully protonated or deprotonated group, respectively. In contrast, if












Table 3.2: Calculated pKa values for His57 and the ligand titratable groups and the corresponding protonation degrees at a pH of 7.8. ∆ncalc corresponds to the
protonation effect considering all pKa shifts observed in the 12 Å sphere; ∆ncalc/HL corresponds to the protonation effects considering the pKa shifts of His57
and the ligand; n.a. = not applicable.
apo complexed
compound ∆nexp ∆ncalc ∆ncalc/HL His57 ligCOO ligAMINO His57 ligCOO ligAMINO
Trypsin 1b 0.9 0.51 0.49 0.43 (7.68) 0.0 (3.21) n.a. 0.92 (8.84) 0.0 (2.69) n.a.
1bMe 0 -0.18 -0.14 0.20 (7.20) n.a. n.a. 0.06 (6.62) n.a. n.a.
1c 0 -0.03 -0.01 0.20 (7.21) 0.0 (4.17) n.a. 0.21 (7.23) 0.0 (3.69) n.a.
1cMe 0 -0.29 -0.21 0.30 (7.44) n.a. n.a. 0.09 (6.80) n.a. n.a.
1d -0.53 -0.14 -0.06 0.29 (7.42) n.a. 0.33 (7.49) 0.00 (5.50) n.a. 0.56 (7.90)
1dAc 0 -0.21 -0.12 0.24 (7.29) n.a. n.a. 0.12 (6.92) n.a. n.a.
2 0.93 0.57 0.54 0.46 (7.73) 0.00 (3.40) n.a. 1.00 (10.92) 0.00 (3.30) n.a.
3 0 0.14 0.15 0.38 (7.59) 0.00 (3.84) n.a. 0.53 (7.85) 0.00 (3.40) n.a.
4 0 0.34 0.36 0.38 (7.58) 0.00 (2.65) 0.32 (7.48) 0.11 (6.91) 0.00 (0.77) 0.95 (9.07)
5 0 0.08 0.1 0.46 (7.73) 0.00 (2.51) 0.59 (7.95) 0.18 (7.13) 0.00 (0.46) 0.97 (9.28)
Thrombin 4 0 0.2 0.26 0.77 (8.32) 0.00 (2.65) 0.32 (7.48) 0.37 (7.56) 0.00 (-0.68) 0.98 (9.56)
5 0 0.15 0.01 0.76 (8.31) 0.00 (2.51) 0.59 (7.95) 0.36 (7.55) 0.00 (-0.85) 1.00 (10.18)
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less pronounced and virtually irrelevant for the protonation inventory (e.g., for pKa 5.0 →
6.0 at pH 7.0 the protonation degree rises from 1% to 8%, for pKa 5.0 → 4.0 at pH 7.0 it
decreases from 1% to virtually 0%). Thus, the maximum effect on the protonation inventory
is experienced at pKa values near the pH.
A pKa shift of one unit is close to the estimated minimum deviation of predicted pKa values
from experimental data based on our calculation method (a root-mean-square deviation of
0.88 pKa units was obtained for a data set of 132 experimentally determined pKa values
[85]). Therefore, with respect to estimates of protonation changes, caution is warranted if
pKa shifts of less than one unit near the pH are observed. This also means that protona-
tion changes of less than 40% (or 0.4 mole transferred protons) are of limited significance
if they are based on a pKa shift of less than one unit (which is possible only at the critical pH).
In the results section, we evaluate the protonation change from the computed pKa shifts for
the buffer pH of the ITC experiments. Rather small pKa shifts near this pH for complexes
with no measured protonation change might lead to the impression that a proton transfer
is falsely estimated. However, such small shifts must be considered in the context of the
limited significance mentioned above. E.g., a protonation change of 0.33 mol based on a pKa
shift from 7.4 to 6.8 at pH 7.0 is not sufficient to postulate a true proton transfer from the
calculations.
Finally, also the experimental error of the ITC measurement should be mentioned, which is
estimated to be ±0.12 mol [22]. Such a protonation change corresponds to a pKa shift of
at least ±0.20 units (if occurring around the solution pH; larger at other pH values). This
needs to be considered for the interpretation of the following results.
3.2.2 pKa Calculations on the complexes
For the binding of 1b (Figure 3.3) to trypsin, ITC detected a proton uptake by the system of
∆nexp = +0.90. Visual inspection of the protein-ligand complex reveals either His57 or the
carboxylate group of the ligand as likely candidates for picking up a proton. The distance
between the Ndelta of His57 and the Asp102 carboxy oxygen OD2 amounts to 2.7 Å, whereas
Nepsilon is 3.7 Å distant from the ligand’s carboxy oxygen (Figure 1a). Furthermore, it
must be noted that the ligand’s carboxylic function is in hydrogen-bond distance (2.9 Å)
to Ser195. In an earlier contribution, we assumed that the carboxy function of ligand 1b
would pick up the proton, simply because the corresponding methylester of 1b did not show
a similar protonation change [22]. The computed pKa values of complexed and uncomplexed
trypsin show a significant shift only for His57. For the apo structure, a pKa value of 7.68
36 3.2 RESULTS
is calculated, whereas for the complex a pKa of 8.84 is suggested. Taking all apparent pKa
shifts into account a net uptake of ∆ncalc/all = +0.51 moles of protons (96 % of this proton
uptake results from the His57 pKa shift) is computed. In contrast, the ligand’s carboxylic
group shows no pKa increase and, obviously, remains deprotonated.
In order to study whether the pKa calculations would suggest unchanged protonation states
for the binding of the ester 1bMe to trypsin a reasonable binding geometry of the ester had
to be generated based on the crystal structure of the acid 1b. A crystal structure could not
be obtained. As both possibilities to attach the methyl group to the carboxylate oxygens of
1b appeared feasible, we performed calculations on the basis of both binding orientations.
However, the two possibilities did not show major differences in the resulting pKa values.
The net change of protonation ∆ncalc/all is predicted to be -0.18.
Shifting the carboxylic group at the piperidine ring (as in 1b) from the 2- to the 4- po-
sition gives 1c. At first glance, this appears to be a minor variation. Both ligands 1b
and 1c place their carboxylic functions in related regions of the binding pocket and, thus,
similar protonation effects might be expected (Figure 1b). However, ITC revealed that no
exchange of protons occurs upon complexation of 1c (we will call this a zero effect). Based
on the calculations, the His57 pKa in the uncomplexed form is 7.21 and remains at 7.23 in
the complex. No further titratable group shows any significant pKa shift giving rise to a
protonation change (∆ncalc/all is -0.03).
Esterification of the ligand’s 4-carboxylic function (1cMe) showed no protonation effect
in the ITC experiment: Complexation of 1cMe with trypsin results neither in proton uptake
nor in proton release. The tendency for a zero effect is predicted correctly by our computa-
tions, although a net value ∆ncall/all of -0.29 is suggested.
Upon binding of trypsin to 1d, the complex shows an overall release of ∆nexp = -0.53
moles of protons in the ITC experiment. Visual inspection of the complex geometry reveals
a similar arrangement of the 1b.Try, 1bMe.Try, 1c.Try and 1cMe.Try complexes: The
piperazine ring of 1d occupies the same region of trypsin as in 1b, 1bMe, 1c and 1cMe
(Figure 1). However, a basic instead of an acidic function is now accommodated in the
S2 pocket. Although the conserved binding mode might imply a very similar situation in
the 1c.Try and 1d.Try complexes, the altered functional group has dramatic influence on
the pKa calculation: It shows irregular (non-Henderson Hasselbalch/non-sigmoidal) titration
curves for His57 and the ligand. Such curves have been observed experimentally [87] as
well as theoretically (mostly in PB calculations) [43, 88, 89, 90]. Two requirements are
necessary to produce irregular curves [91]: (1) The electrostatic interaction between the two
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groups has to be strong, and (2) they must titrate in the same pH range. In the case of
the 1d.Try complex, the two requirements are fulfilled: The strong interaction is caused by
close proximity of the titrating groups; their mutual distance measured between the titrating
nitrogen atoms amounts to 4.1 Å. Furthermore, the two nitrogen functionalities titrate in
the same pH range since they are both bases and experience similar intrinsic pKa values
(the intrinsic pKa value of a titratable group corresponds to its pKa value when all other
titratable groups are in the neutral state): the intrinsic pKas of His57 and the ligand are 5.38
and 7.07, respectively. In analogy to Trylska’s treatment of the coupled system of the two
aspartates in the catalytic dyad of HIV protease [52], the two titration curves (His57/ligand)
are superimposed and the His57/ligand piperazine system is considered as one coupled base
system. Evaluating this titration curve, the following pKa values can be extracted: His57
experiences a downward pKa shift from 7.42 to 5.59, whereas the pKa value of the ligand’s
secondary amino group changes from 7.49 (in aqueous solution) to 7.90 (in the complex). The
resulting net protonation change (upon ligand binding) is estimated to be ∆ncall/all = −0.14.
The experimentally observed deprotonation occurring upon 1d complexation by trypsin
can be prevented by acetylating the secondary nitrogen of the piperazine ring. This is also
evidenced by ITC measurement of the corresponding 1dAc.Try complex. Our pKa calcula-
tions yielded a ∆ncall/all of -0.21.
Ligand 2 differs structurally from the 1b-d series (Figure 3). The pKa calculation for
the 2.Try complex yields a protonation change of ∆ncall/all = +0.57 (95 % of this ∆n result
from an upward pKa shift of His57). The ITC experiment showed a net proton uptake of
∆nexp = +0.93.
Inhibitor 3 also bears a carboxylic function, but it differs structurally from the 1b-d series
(Figure 3). However, as the crystal structure 3.Try shows, its carboxylate is hydrogen-
bonded to Gln174, which is more than 7 Å apart from Ser195 and more than 8 Å of from
His57. Furthermore, the acidic group is strongly exposed to the adjacent solvent environ-
ment. ITC reveals no protonation effect upon binding of 3 to trypsin, the calculations give
∆ncalc/all = +0.14.
The remaining two ligands for which pKa calculation were performed also differ struc-
turally from the previous ligands. For both ligands, complex crystal stuctures with trypsin
and thrombin have been determined. Interestingly, the ligands do not bear any aromatic side
chain to address the S3 pocket, and they bind with their guanidino (4) or benzamidino group
(5) into the S1 pocket (Figure 1d). The ligands have two titratable groups in common: a
terminal carboxylic group and a secondary amine, separated by two bonds. In the crystal
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structure, these groups are more than 9 Å remote from His57 and, thus, only marginal
influence on its pKa value is expected. Indeed, rather small pKa shifts for His57 are observed
in the pKa calculations (see Table 3.2). The ITC experiment showed no proton exchange
when 4 or 5 bind to trypsin or thrombin. The following overall changes in protonation were
obtained (the values for thrombin are given in parenthesis): ∆ncalc/all is +0.34 for 4.Try
(+0.20 for 4.Thr), while for 5.Try ∆ncalc/all is 0.08 (+0.15 for 5.Thr).
Besides the above-described pKa shifts, there are further titratable groups that experience
changes in pKa values upon complex formation in all considered complexes. For example,
Asp189 in the S1 pocket of trypsin shows a downward pKa shift (mean pKa value for apo
trypsin: 4.3, mean pKa value for complexed trypsin: 2.6). Tyr228, also contributing to the
S1 pocket, is involved in another downward pKa shift: it changes from 12.5 (mean pKa value
in apo trypsin) to 11.5 (mean pKa value in complexed trypsin). However, these shifts do
not provoke any change in overall protonation. Therefore, they can be neglected for the
interpretation of the observed net release or uptake of protons.
3.3 DISCUSSION
Our pKa calculations evidence that the protonated His57 and the deprotonated ligand 1b
form a salt bridge-like electrostatic interaction. At first glance, this suggests that the place-
ment of a charged carboxylate group next to the catalytic triad would generally induce a
protonation change of His57. However, as 1c.Try shows, this is not the case. Closer inspec-
tion of the 1c.Try complex shows that the ligand’s carboxy oxygen (O55) is 5.1 Å apart
from Nε of His57, which corresponds to an expansion of 1.4 Å compared to 1b.Try. In
addition, the distance between Ser195 oxygen Oγ and the ligand’s oxygen (O55) is increased
from 2.9 to 7.5 Å. Most likely, these expanded distances alter the electrostatic properties of
the complex (1c.Try) significantly. Accordingly, the pKa calculation suggests no change in
protonation for His57 which is in agreement with experiment. Purely based on structural
terms (without any pKa calculation), it would be difficult to predict such a zero effect for
the latter complex.
For the 1d.Try complex, the results deviate from the experimental finding. Originally,
it was assumed that a downward pKa shift would only occur at the ligand’s amino group
upon trypsin binding [22]. The pKa calculation suggests His57 to undergo a significant down-
ward pKa shift, along with a rather marginal upward pKa shift for the ligand. Although
the ligand’s pKa value changes by less than 0.5 log units, it almost outweights the effect on
His57. This example shows that a small pKa shift in the physiological pH range may result
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in a very complex picture of mutually compensating effects which prevent a straight-forward
interpretation of experimentally observed protonation changes. The calculations suggest
a correct trend for the net change in protonation of 1b.Try, the quantitative agreement,
however, is unsatisfactory. Nevertheless, assessing the relevance of such calculations, one has
to bear in mind the range of experimental error and the reduced accuracy in pKa estimations
that result for the present example from coupled titration curves. These are much more
difficult to handle and allow only for crude pKa predictions.
The positions of the carboxylate of ligand 2 in trypsin and thrombin are similar. Both
complexes show almost equal protonation effects in the ITC experiment (2.Thr ∆ncalc/all =
+0.88; 2.Try ∆ncalc/all = +0.93). For both ligands, the esterified form has also been com-
plexed with trypsin and thrombin and measured by ITC, and it was observed that a zero
effect results. Accordingly, it was originally assumed that the pKa shift in 2.Thr and 2.Try
occurs at the carboxylic group of the ligand [22]. In a previous computational study [85], we
could correctly predict the effect for 2.Thr using the available crystal structure. For 2.Try,
only a docked structure served as starting geometry for the pKa calculation since no corre-
sponding crystal structure is available. Possibly, this explains the somewhat less satisfactory
quantitative agreement of experiment and computer prediction for 2.Try (∆∆n = 0.36)
compared to 2.Thr (∆∆n = 0.28).
The computer simulations suggest that the two ligand titratable groups of 4 and 5 tend
to adopt a zwitterionic state when complexed to the protein. The amino group and the
carboxylate form a strongly coupled electrostatic system over short distance which induces
a downward pKa shift for the carboxylate and an upward shift for the amino group. While
the downward pKa shift does not alter the protonation state for the carboxylic group, the
upward pKa shift of the amino function suggests a protonation change from the neutral to
the positively charged state. Rather small pKa shifts of the amino function are suffcient
to provoke this net change; e.g. for 4 (pKa(aq) = 7.48), a pKa shift of +0.5 units induces
a protonation change of +28 % (-0.5 units: -19 %) referring to a buffered solution of pH
7.8. The net protonation inventory resulting from the pKa shift of the amino groups in 4
and 5 might be partially compensated by a downward pKa shift of His57, but still a value
deviating from zero results as ∆ncalc. Interestingly, if one of the two ligand titratable groups
is considered as permanently charged and, thus, not involved in protonation changes, the
measured zero effect is much better predicted by the simulations. This may indicate that the
site-site interaction between the ligand titratable groups is overestimated in the pKa calcula-
tion and prevents quantitative agreement. Nevertheless, for three of the four complexes the
zero effect is correctly indicated if we consider all ∆ncalc values smaller than 0.2 as negligible
(cf. Section 2.1 and 4).
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3.3.1 Influence of conformational variations
To assess the influence of slightly different conformations on the computed pKa values, we
used the crystallographically determined apo structure of trypsin (1TGN) along with nine
artificially generated uncomplexed structures (”ligand-deleted trypsin”, obtained by removing
the bound ligand) to determine the pKa values of uncomplexed trypsin. The pKa of His57
in 1TGN is 7.88. Analyzing all calculations on the nine ligand-deleted trypsin structures
(cf. Table 3.2) unveils a slight variation of the pKa for the crucial residues His57 (7.49
±0.19) and Asp102 (1.99 ± 0.36). This suggests that the uncertainties in our calculations
will be at least in the range of the estimated experimental error of ITC measurements and
provides an additional approximation about the significance of the computed pKa shifts.
The strategy of using the ligand-deleted trypsin structures appeared justified, as Guvench et
al. [92] had previously shown by MD simulations that a high structural conservation of the
trypsin binding pocket is given. The overall RMSD based on a Cα-fit between 1TGN and
our trypsin complexes ranges between 0.28 and 0.42 Å, which illustrates the low degree of
flexibility of the trypsin structures in response to ligand binding.
3.3.2 pKa values of histidine residues
Finally, it may be instructive to examine the spread of experimentally observed pKa shifts of
histidine residues in proteins as an example to estimate the impact of the protein environment
on pKa values. While in our calculations for the different complexes the pKa of His57 varies
over a range of approximately 5 units, the experimental pKa values of histidines in various
protein structures are reported to be distributed over more than seven pH units [93]. His149
in Bacillus circulans shows a value below 2.3 [94]. In contrast, the pKa values of His66 and
His72 in a protein tyrosine phosphatase are 8.3 and 9.2, respectively [4]. The pKa value of
His31 in T4 lysozyme is 9.1, caused by the formation of a salt bridge to Asp70 (pKa = 0.5)
[95]. In a recently published data base [96], more than 300 pKa values for histidine residues
are available: The mean value is 6.33 (standard deviation of 1.35); 35 deposited histidine
residues exhibit a pKa value greater than 7.5. The experimental pKa for His57 in rat trypsin
is 6.7 (NMR- measurement for a D189S mutant) [97], whereas the pKa value of the imidazole
moiety of the free amino acid in water has been determined to 6.3 [98].
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3.4 Conclusions
In this study, systematic investigations about protonation changes in due course of ligand
binding to trypsin and thrombin have been performed. The trend for the nine complexes
which show a zero effect in ITC could be predicted correctly. This conclusion is based on
the following trends in the calculations of ∆ncalc/all: -0.18 (1bMe.Try), -0.03 (1c.Try),
-0.29 (1cMe.Try), -0.21 (1dAc.Try), +0.14 (3.Try), +0.34 (4.Try), +0.08 (5.Try), +0.20
(4.Thr), +0.15 (5.Thr). On average, a net change of ± 0.18 moles of protons (with a stan-
dard deviation of 0.09) is suggested. This has to be faced with the experimental accuracy
which is estimated to be ± 0.12 [22]. Larger deviations are observed for those complexes
where most likely a coupled system of titratable groups exists. For the trypsin and thrombin
complexes where ITC suggests a net change in the protonation inventory also the calcula-
tions indicate the correct trends. For one complex (1d.Try) only the correct tendency is
suggested, again obviously a case with strongly coupled titratable groups. Such groups de-
viate from simple Henderson-Hasselbalch behaviour and complicate straightforward handling.
The present calculations allow structural interpretation of protonation states in conjunc-
tion with ITC measurements. ITC experiments give access to the Gibbs free energy ∆G
along with the heat absorbed or produced during complex formation. This heat contains the
binding enthalpy, but changes in protonation states may be superimposed. This is due to
the fact that any release or pick-up of protons involves a heat of ionization of the functional
groups, which concerns not only the functional groups of the buffer molecules, but also the
groups of the protein residues or the bound ligand that change their protonation state. In
this context, it matters dramatically whether the groups involved in the protonation reaction
exhibit oxygen or nitrogen functionalities.
In our previous communication [22] we falsely assumed that the carboxylate function of
1b and 2 would undergo protonation upon trypsin and thrombin binding. This interpre-
tation was born out of the simple conclusion that the corresponding esters of 1b and 2
did not show any protonation changes. Accordingly, we corrected for a heat of ionization
contribution of 2.26 or 0.84 kJ/mol [22], resp., for the acidic oxygen functions. After sub-
straction of this contribution from the measured heat, a net ∆Hbind of -45.6 kJ/mol for
1b.Try was assumed. The measured ∆Gbind was then factorized into enthalpy and entropy.
The calculations presented in this study suggest that the carboxylic function of the ligand
remains deprotonated, whereas His57 picks up a proton. This now involves ionization of a
nitrogen functionality which produces a much higher heat contribution (∆Hion of His: 30
kJ/mol; taken from http://www.lsbu.ac.uk/biology/enztech/ph.html). Accordingly, ioniza-
tion of His57 upon complex formation of 1b with trypsin requires a correction of 27 kJ/mol
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(0.90×30 kJ/mol). After substraction of this value from the measured heat, a quite different
value for ∆Hbind = −20.6 kJ/mol remains. In consequence, this suggests a strongly deviating
factorization in enthalpic and entropic contributions. For the complexes of 2, similar correc-
tions have to be performed (Table 3.3). Accordingly, the interpretation of the driving forces
responsible for binding of 1b and 2 to the considered serine proteases has to be modified
(Table 3.3). Binding is now characterized by a significantly smaller enthalpic contribution
and a more favorable entropic contribution. The originally suggested pronounced enthalpic
binding of 2 to thrombin is now reduced and thus better comparable with data of the other
ligands in the series. Furthermore, the formerly contrasting partitioning for the complexes
of acid 1b and ester 1bMe with trypsin is now suggested to be of equal size for both in-
hibitors. Even though the stronger binding of napsagatran (2) to thrombin results (still)
from a stronger exothermic binding compared to the ester, the entropic advantage of the
ester compared to the acid is much less pronounced according to the new partitioning.
For 1d.Try a more complex protonation transfer is suggested by the computer simulations.
However, with respect to the partitioning of enthalpy and entropy the assignment of heat of
ionization corrections remains virtually unchanged because the amount to be corrected for
the histidine residue is very similar to that of the ligand’s piperazine moiety. Accordingly, no
significant changes with respect to our previous interpretation and factorization for 1d.Try
are required.
In summary, protonation changes can lead to very different factorization into enthalpy
and entropy depending on the involved ionizable groups. The pKa calculations presented in
this communication can support the thermodynamic characterization and interpretation of
the protein-ligand binding process, if protonation effects are superimposed. The experimen-
tal efforts to fully characterize protonation changes are quite elaborate and consume large
amounts of expensive protein material. In contrast, the presented calculations are cheap
and fast to perform. As such they can provide valuable assistance in properly planning and
analyzing ITC experiments.
3.5 Materials and Methods
The investigated ligands are shown in Figure 3. Most of them contain three titratable
groups: a guanidino group, a sulfonamide or secondary amino group, and a carboxylic acid
group. For all ligands, experimental pKa values have been determined [22]. In the present
pKa calculations, only the carboxylic acid and secondary amino group were considered as




















Table 3.3: Corrected factorization of enthalpic and entropic binding contributions from ITC experiments. All energy values are given in kJ/mol.
complex ∆nobs ∆ G ∆Hx ∆H





1b 0.9 ±0.6 -36.4 -47.6 ±1.9 2 30 -45.6 -20.6 9.2 -15.8
1bMe.Try 0 -37.0 -16.9 ±0.8 not necessary not necessary -16.9 -16.9 -20.6 -20.6
2.Try 0.93 ±0.12 -32.0 -32.3 ±3.6 0.8 30 -31.5 -4.4 -0.5 -27.6
2.Thr 0.88 ±0.08 -52.2 -75.1 ±1.8 0.8 30 -74.4 -48.7 22.2 -3.5
2Et.Thr 0 -40.3 -24.4 ±0.9 not necessary not necessary -24.4 -24.4 -15.9 -15.9
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the complexes is shown in Figure 1. The following complex crystal structures (referred to
by their PDB code) were used as starting geometries: 1K1I (1b.Try), 1K1J (1cMe.Try),
1K1L (1d.Try), 1K1M (1dAc.Try), 1K1N (3.Try), 1K1O (4.Try), 1K1P (5.Try); for
thrombin, the complexes 1K21 (4.Thr) and 1K22 (5.Thr) were evaluated. A geometry of
the trypsin complex with 1c was generated by replacing the methylester of 1cMe.Try with
a carboxylic acid group. Subsequently, the modelled complex was energy minimized with the
program MOLOC using the MAB force field [99]. The geometry of the complex 1bMe.Try
was generated similarly in reverse fashion by attaching a methyl group to either oxygens of
the carboxylic function of 1b; thus, both possibilities for ester formation have been explored.
A 3D-structure of the 2.Try complex was obtained by docking using GOLD [100]. 1K1P
was chosen as template structure, and 20 docking poses were generated and evaluated. The
rank 3 solution was selected for the pKa calculation based on its convincing agreement with
the thrombin/napsagatran crystal structure [22].
For the pKa calculations, the same methodology as recently described by us was applied
[85]. To study the protonation effects upon ligand binding, two pKa calculations are re-
quired: One without ligand and a second with the bound ligand. MEAD was employed
as PB solver (using a dielectric constant of 20 for the protein) [64], REDUCE was used to
generate hydrogens for the residues of the protein [75]. SYBYL was applied to add hydrogens
to the ligands [101]. Only the titratable residues within a 12 Å sphere around the active
site were selected for evaluation of the site-site interactions in order to reduce the computa-
tional effort (in total, there are 39 titratable residues in trypsin and 81 in thrombin). This
results in the following titratable residues for trypsin: Tyr39, His40, His57, Tyr59, Lys60,
Tyr94, Asp102, Lys145, Tyr151, Tyr172, Asp189, Asp194, Lys224, Tyr228. In the case
of thrombin, the following titratable residues lie within the sphere: Glu18, Glu39, Asp56E,
His57, Tyr60A, Lys60F, Tyr94, Glu97A, Asp100, Asp102, Lys145, Glu146, Lys169, Tyr184A,
Asp189, Glu192, Asp194, Glu217, Asp221, Asp222, Lys224, Tyr225, Tyr228.




































































Figure 3.3: Chemical formulae of the ligands studied by Dullweber et al. [22] and used in this investigation;
for clarity the original numbering used from the previous contribution is maintained without changes.
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4 ATYPICAL PROTONATION STATES IN THE
ACTIVE SITE OF HIV-1 PROTEASE: A
COMPUTATIONAL STUDY
4.1 INTRODUCTION
The Acquired ImmunoDeficiency Syndrome (AIDS) is a disease affecting the human im-
mune system first characterized about 25 years ago. The causative agent of this disease is
the retrovirus named Human Immunodeficiency Virus (HIV) [102], which appears in two
forms, HIV-1 and HIV-2. The best-studied drug target of the virus is the HIV-1 protease
(HIVP). Currently, there are eight approved drugs on the market that aim at the inhibition
of HIVP (http://www.hiv.net). Besides its significant pharmaceutical relevance, HIVP is a
prominent example for atypical protonation states in the active site [25, 24, 103, 26]. In
this context, atypical protonation means a non-standard protonation, i.e. a protonated acid
or a deprotonated base. We therefore selected this target to study the predictive power
of Poisson-Boltzmann-based pKa calculations using our newly developed PEOE PB partial
charge model [85].
HIVP forms a symmetric homo-dimer, with each chain containing 99 residues. The cen-
tral core of the dimer forms the active site (see Figure 4.1). The reaction catalyzed by HIVP
is a peptide-bond cleavage, usually between a Tyr and a Pro or between a Phe and a Pro.
The binding pocket is composed of the catalytic triad Asp-Thr-Gly. The two aspartates (one
from each domain of the homo-dimer) are of main relevance, and are therefore named the
catalytic dyad. Besides the central cavity which is formed by the active site, three specificity







ficity pockets preferably accommodate the hydrophobic parts of the ligand, which are named







Two design strategies have been followed in the development process of HIVP inhibitors:
in the first generation, it was attempted to mimic the transition state by peptidomimetics
mostly with one central hydroxylic group donating a hydrogen bond to the catalytic dyad.
Inhibitors of the second generation contain a carbonyl group mostly embedded into a central
ring moiety to displace the ”flap water”. The latter is a conserved water molecule hydrogen-
bonding to the flap region via Ile50; the flap region of HIVP is the highly flexible part of the
protein. This flap water is a special structural element unique for this viral protease. We
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Figure 4.1: The complex formed by HIVP with the inhibitor VX-478 (Amprenavir, see Figure 4.2): the
ligand, the catalytic dyad and Ile50 of the flap region are shown in stick representation. The flap water,
hydrogen-bonding to the backbone of Ile50, is given as a red sphere.
will perform systematic studies on the inclusion or exclusion of this water molecule to study
the relevance of explicitly considered water molecules for future pKa calculations.
The five inhibitors that were considered in our study are shown in Figure 4.2. KNI-272,
VX-478 and S6 represent members of the first generation of HIVP inhibitors, while DMP-
323 and S7 belong to the second generation. The ligand DMP-323 induces a protonation
change of the catalytic dyad: from the apo state with one of the two aspartates protonated
[25, 24] to a double-protonated state with both aspartates uncharged [103]. Thus, obviously
HIVP displays already as apo enzyme an atypical protonation state for the catalytic dyad,
which can be modulated upon ligand binding. The correct prediction of such effects displays
the main focus of our computational study. We start with calculations for the uncomplexed
and complexed HIVP where experimental data on the adopted protonation states are avail-
able. This will give insight into the power of our method to correctly predict protonation
states and will serve as a benchmark study. Furthermore, we will face our results to a former
computational pKa study on HIVP complexes [52]. Finally, we will predict the protonation
states for HIVP complexes where up to now no experimental data on the protonation states
















































Figure 4.2: Inhibitors of HIVP used for the pKa study: DMP-323, KNI-272, S6, S7 and VX-478.
4.1.1 Setting of the dielectric constant and handling of coupled systems
Prior to the discussion of possibly limiting factors, we will start with a brief introduction to
PB-based pKa calculations. Three different energy contributions to the ∆G of a protonation
reaction are determinant for the final pKa value and provoke the shift from the model pKa
value, pKmoda , (corresponding to the pKa value of the isolated residue in aqueous solution) to
the pKa value in the actual protein environment: the solvation energy, the background inter-
action energy, and the site-site interaction energy. The solvation energy considers the penalty
from the desolvation; the interaction with the permanently present dipoles and charges is
represented by the background interaction; the interaction of the titratable residues with each
other is covered by the site-site interaction energy term. The first two quantities represent
the intrinsic pKa value (pK inta ): although they are artificial (all titratable residues besides
the one of interest are in the neutral state) and cannot be experimentally detected, they
possibly indicate the predominance of one contribution. The consideration of the site-site
interactions reveals the final pKa value in the protein environment.
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One central point of discussion with respect to pKa calculations is the choice of the protein
dielectric constant (εProtein). The interested reader is referred to Warshel’s excellent review
on this topic [34]. In previous studies, it was shown that the best overall agreement (with the
experimentally determined pKa values) can be achieved setting εProtein to 20 [18, 85]. How-
ever, the analyses primarily involved solvent-exposed residues which show only minor pKa
shifts. For active-site residues experiencing large pKa shifts, the assignment of εProtein = 4
generates better results. This could be shown for lysozyme (Glu35: pKaexp=6.2) [18, 85]
and xylanase (Glu172: pKaexp=6.7) [85]. Competitive studies illustrate a broad range of
applied dielectric constants: Demchuk and Wade used in their PB-based pKa calculations
εProtein of 80 for solvent-exposed residues and 15 for desolvated sites [19]. Nielsen et al.
used a single value of 8 for all residues [21, 80]. King et al. found in microscopic MD
simulation studies that the (macroscopic) dielectric constant could be as high as 10 in sites of
catalytic importance [104]. This shows that there is no universal value for εProtein. In order
to validate our pKa calculation methodology, and having experimental data for some of the
studied complexes as a reference, we performed our pKa calculations at three different values
of εProtein: 4, 10 and 20. These values cover a large range for the dielectric constant of the
protein, and we hope in light of the experimental reference points to draw some conclusion
concerning the preferred setting of εProtein.
A second issue of pKa calculations on HIVP structures concerns electrostatically strongly
coupled systems. The two aspartates of the catalytic dyad undergo a strong mutual interac-
tion on short distance resulting in such a system. This was previously reported in the pKa
study on HIVP of Trylska et al. [52] and can also be observed in our calculations. The two
aspartates approach each other in space by approximately 3 Å. This proximity leads to the
formation of a coupled system and results in a significant non-sigmoidal behaviour (see Figure
4.3, thin lines). With respect to the computational setup, in the case of strongly coupled
systems, it is necessary to perform a post-processing step after the actual pKa calculation.
This was done in analogy to Trylska et al. [52], who superimposed the single titration curves
of Asp25 and Asp25’. This gives a titration curve similar to that of a diprotic acid, e.g.,
maleic acid. The pKa values for the two aspartates correspond then to the situation where
ΣH+ = 1.5 and 0.5, corresponding to 25 or 75 % protonation of the two coupled aspartates
(see Figure 4.3, thick line and horizontal lines).
4.2 MATERIALS AND METHODS
MEAD was employed as PB solver [105]. The settings of the pKa calculations and computa-
tional details to our developed PEOE PB partial charges are given elsewhere [85]. PDB2PQR
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Figure 4.3: Titration curves of apo HIVP (crystal structure 1HHP, εProtein = 10). The individual titration
curves of the virtually independent aspartates are shown as thin (solid and dashed) lines, both curves
are almost indistinguishable. The superimposed titration curve of the coupled diprotic acid system is
given as thick line. The dashed straight lines at 1.5 and 0.5 correspond to situations of the coupled
system where either 25 % or 75 % of both aspartates are protonated (corresponding pKa values are
here 4.22 and 6.89).
was used to generate hydrogens for the protein residues [27]. A direct comparison to our
former model [85] for the simulation of the uncharged form of aspartate and glutamate in
which implicit hydrogens were placed to model the neutral state showed an improvement
when using explicit hydrogens instead. Therefore, we placed explicit hydrogens on the OD2
(Asp) and OE2 (Glu) atom. SYBYL was applied to add hydrogens to the ligands [106].
Manual adjustment of the considered local conformation was done for the central hydrox-
ylic groups of the ligand being in close contact to the catalytic dyad (named ”rot-scan”).
Where available, experimental knowledge about the formed hydrogen bonds was used: this
is the case for the symmetric cyclic urea compound DMP-323 [103] and the asymmetric
peptidomimetic KNI-272 [26]. In case pKa calculations were performed considering explicit
water molecules, the orientation of the hydrogen atoms was manually adjusted.
To study the protonation effects upon ligand binding, two pKa calculations are required: one
without the bound ligand and a second with the bound ligand. The net protonation effect is
the resulting difference between the degrees of protonation between the two forms. The pro-
tonation states are calculated at a pH of 5.0, as HIVP optimally catalyzes the peptide bond
cleavage within a pH range of 4.0 and 6.0 [24]. The notation H+ is used for the protonation
4.2 MATERIALS AND METHODS 51
degree of one particular residue, i.e. H+ = 1.0 corresponds to full protonation and H+ = 0.0
to full deprotonation. The notation ΣH+ describes the sum of the protonation degrees for
the complexed and uncomplexed form of the protein-ligand system. The following crystal
structures (given by their PDB codes) for complexed and uncomplexed HIVP structures were
used: 1HHP (apo), 3HVP (apo), 1HPX (KNI-272), 1QBS (DMP-323), 1XL5 (S6), 1XL2
(S7), 1HPV (VX-478). The ligands are given in Figure 4.2.
The structural differences between the two apo structures are rather marginal: the Cα
fit gives an RMSD value of 0.40 Å, and both crystal structure show the same space group
(P41212). Their resolution is 2.7 Å (1HHP) and 2.8 Å (3HVP). A comparison of the apo
structures and the complexes reveals Cα-RMSD values between 0.96 and 1.35 Å. The com-
plexes are structurally more similar among each other: the RMSD lies betwen 0.47 and 0.77
Å. The resolution of the complexes is higher compared to the apo structures and ranges
between 1.5 and 2.0 Å. The complexes appear in different space groups: P212121 (1XL2),
P61 (1QBS, 1HPV), P21212 (1XL5).
We calculated pKa values for the following titratable residues (predefined model pKa values
are given in parenthesis): aspartate (4.0), glutamate (4.4), histidine (6.3), cysteine (8.7),
tyrosine (9.6), lysine (10.4). The pKa values of the C- and N-termini were not considered,
since they are 18 Å apart from the catalytic dyad and assumed to remain in their standard
protonation state upon complexation. With respect to the ligands, only S7 contains a titrat-
able group, which is a pyrrolidine ring.
In Table 4.1, the slight differences in the primary sequences of the evaluated HIV-1 pro-
teases are listed. In the case of the 3HVP structure, all mutations to natural amino acids
Table 4.1: Comparison of HIVP sequences (Aba: α-amino-N-butyric acid; Cso: S-hydroxycysteine).
Position 1HHP/1HPX 3HVP 1QBS 1XL2/1XL5 1HPV
3 Ile Ile Val Ile Ile
14 Lys Arg Lys Lys Lys
37 Ser Asn Ser Ser Ser
41 Arg Lys Arg Arg Arg
63 Leu Pro Leu Leu Leu
64 Ile Val Ile Ile Ile
67 Cys Aba Cso Cys Cys
95 Cys Aba Ala Cys Cys
regard solvent-exposed residues and occur at least 16 Å from the catalytic dyad. Mutations
to non-natural amino acids such as Aba and Cso (3HVP, 1QBS) are observed at least 10
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Å apart from the catalytic center and thus, the influence on the catalytic dyad should be
marginal. These residues (Aba, Cso) were mutated to cysteine for the pKa calculations.
4.3 RESULTS
4.3.1 Calculations on two apo structures
In Table 4.2, the experimentally determined pKa values (determined via kinetic measure-
ments) for apo HIVP are listed, which suggest mono-protonation for the catalytic dyad at a
pH of 5.0. Whereas the experimental range for the first titration step of the coupled aspar-
Table 4.2: Experimentally determined pKa values for the two catalytic aspartates in apo HIVP. The two
ranges from reference [25] result from measurements on different substrates.
pKa1 pKa2
(aspartate1) (aspartate2)
reference [25] 3.4-3.7 5.5-6.5
reference [25] 3.1-3.3 4.9-5.3
reference [24] 3.3 6.8
tates falls into a range between 3.1 and 3.7 the second step has been determined to occur
between 4.9 and 6.8. The spread of nearly two log units makes a comparison to our computed
results difficult. However, the protonation state at pH of 5 appears well-characerized and
suggests mono-protonation of the catalytic dyad. The results from NMR experiments [107]
are not listed, since they only provide a range (< 5.9) for both pKa values.
The results of our pKa calculations taking the two different apo protein structures (1HHP,
3HVP) as starting geometries are given in Table 4.3 and 4.4. They show that the computed
Table 4.3: pKa calculations on apo HIVP (1HHP).
(Trylska et al. [52])
εProtein pKa1 H
+ a pKa2 H
+ a ΣH+ b pKa1 H
+ a pKa2 H
+ a ΣH+ b
(aspartate1) (aspartate2) (aspartate1) (aspartate2)
4 6.06 0.92 9.90 1.00 1.92 3.4 0.02 6.9 0.99 1.01
10 4.37 0.19 6.97 0.98 1.17
20 3.58 0.04 5.93 0.89 0.93 3.1 0.01 5.3 0.67 0.68
anet degree of protonation of aspartate1 or aspartate2 at pH=5
bnet degree of protonation of the dyad at pH=5
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Table 4.4: pKa calculations on apo HIVP (3HVP).
(Trylska et al. [52])
εProtein pKa1 H
+ a pKa2 H
+ a ΣH+ b pKa1 H
+ a pKa2 H
+ a ΣH+ b
(aspartate1) (aspartate2) (aspartate1) (aspartate2)
4 4.83 0.40 9.69 1.00 1.40 2.1 0.00 6.7 0.98 0.98
10 3.17 0.01 6.62 0.98 0.99
20 2.65 0.00 5.44 0.73 0.73 2.9 0.01 5.3 0.67 0.68
anet degree of protonation of aspartate1 or aspartate2 at pH=5
bnet degree of protonation of the dyad at pH=5
results are in better agreement with the experimental values once the higher εProtein (20) is
chosen. Decreasing the value of εProtein results in increasing pKa differences between the two
acids; in all cases, the difference is at least two log units. Nonetheless, the net protonation
state of the two catalytic aspartates can be correctly predicted by five of the six pKa calcu-
lations shown in Table 4.3 and 4.4. Thus, both starting geometries seem appropriate over a
wide range of εProtein to correctly predict the mono-protonated state of the catalytic dyad
at a pH of 5.0.
From a structural point of view, both apo structures are very similar: a Cα-fit reveals a
root mean square deviation (RMSD) of 0.4 Å. Similarily, the catalytic triad is structurally
conserved: the RMSD values amount to 0.5 Å (Asp25), 0.06 Å (Thr26), 0.59 Å (Gly27) after
the Cα-fit for all Cα atoms. The distances between the oxygens of the catalytic dyad of the
different apo structures vary by about 0.2 Å.
Similar PB-based pKa-calculations were performed for several complexed and uncomplexed
HIVP structures by Trylska et al. [52]. For comparison, the results from this study are shown
in the last two columns of Table 4.3 and 4.4. They used different values for εProtein in combi-
nation with two different charge models (full-charge: εProtein = 4; single-site: εProtein = 20).
The single-site model handles ionization by adding ±1 point charge to one central atom [18]
(using CHARMM22 charges and OPLS radii), whereas in the full-charge model the formal
charges are distributed over several atoms [108] (using PARSE charges and radii). The
latter treatment is more similar to our charge model. Using a dielectric constant of 20, the
differences between our results and the study of Trylska et al. are smaller than one log unit.
For the calculations with εProtein = 4, larger deviations are observed.
54 4.3 RESULTS
4.3.2 Calculations for the complexes
Uncharged symmetric cyclic urea inhibitor DMP-323
DMP-323 is a symmetric cyclic urea derivative which binds with a Ki-value of 340 pM
[109]. Its benzyl moieties are accommodated in the S1,S
′
1-pockets, whereas the benzyl alco-
hol portions address the S2,S
′
2-pockets. The structural differences with respect to the apo
HIVP structure (1HHP) are relatively large: the RMSD of the Cα-fit amounts to 1.35 Å.
However, this difference is mostly provoked by the flap region, which is known to be rather
adaptive [110]. The carbonyl group of the cyclic urea ring displaces the flap water, which
was one of the initial goals in the development of this type of inhibitor.
The experimentally determined pKa values of the two catalytic aspartates in the DMP-
323 complex are > 7.2 [103] suggesting that both residues are protonated at pH = 5. The
pKa values of all other aspartates and glutamates have also been determined by NMR ex-
periments. Of these, only Asp29 deviates by more than one log unit from its model pKa,
exhibiting a pKa value between 1.97 and 2.06. This lowered pKa value is induced by the
formation of salt bridges to Arg8 and Arg87’.
The results for the DMP-323/HIVP complex are given in Table 4.5. We focus mainly
on the correct determination of the proton uptake upon ligand binding. To correctly predict
this effect, ∆ΣH+ must be +1, since the catalytic dyad changes from mono-protonation
to double-protonation upon ligand binding. This quantity is comparable to ∆n (molar net
exchange of protons), which can be measured using ITC. In a previous study, we successfully
predicted such ∆n for a series of trypsin and thrombin complexes by means of similar pKa
calculations [111]. For the DMP-323 complex, the uptake of additional protons is qualita-
tively correctly predicted, but quantitatively the full amount of one proton on molar ratio is
not accurately estimated: we compute an uptake of +0.63 protons (εProtein = 10). However,
we consider this as a correct prediction of the trend. Furthermore, the pKa shifts of the
catalytic dyad for this εProtein amount to +1.6 and +3.5. Such changes can be considered as
significant enough to assume protonation of both aspartates. Applying a dielectric constant
of 4 or 20 the prediction is less satisfactory, though the correct direction of the pKa shifts is
suggested.
A comparison of our results for the DMP-323 complex with the study of Trylska et al.
is given in Table 4.6. It can be seen that (using εprotein = 20) the difference is less than one
log unit. The aspartate with the lower pKa value seems to be overestimated in our calcula-












Table 4.5: pKa calculations on HIVP complexed with DMP-323 (1QBS).
apo (ligand-deleted) complexed with DMP-323
ε pKa1 H
+ a pKa2 H
+ a ΣH+ b pKa1 H
+ a pKa2 H
+ a ΣH+ b ∆ΣH+ c
(”aspartate1”) (”aspartate2”) (”aspartate1”) (”aspartate1”) ≈ ∆n
4 5.79 0.86 10.19 1.00 1.86 9.96 1.00 20.34 1.00 2.00 +0.14
10 3.73 0.05 7.20 0.99 1.04 5.30 0.67 10.71 1.00 1.67 +0.63
20 2.97 0.01 5.95 0.89 0.90 3.62 0.04 7.06 0.99 1.03 +0.13
anet degree of protonation of aspartate1 or aspartate2 at pH=5
bnet degree of protonation of the dyad at pH=5
cnet change of protonation upon ligand binding
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Table 4.6: Comparison with results from Trylska et al. for the HIVP/DMP-323 complexes. PEOE PB
stands for our charge model used throughout the pKa calculations.
HIVP complexed with DMP-323
PEOE PB Trylska [52] NMR [103]
pKa1 H
+ a pKa2 H
+ a pKa1 H
+ a pKa2 H
+ a pKa1 pKa2
ε = 4 9.96 [1.00] 20.34 [1.00] 7.9 [1.00] 20.5 [1.00] > 7.2 > 7.2
ε = 20 3.62 [0.04] 7.06 [0.99] 3.6 [0.04] 6.5 [0.97] > 7.2 > 7.2
anet degree of protonation of aspartate1 or aspartate2 at pH=5
with experiment, at least for the aspartate with the lower pKa. Concerning the extreme pKa
values (>20), the authors argue that such values are unreasonable; nevertheless, also these
calculations indicate that both residues definitely remain protonated.
Uncharged asymmetric inhibitor KNI-272
The asymmetric inhibitor KNI-272 differs significantly from the cyclic urea compound stud-
ied in the previous section (see Figure 4.2). The inhibitor binds with a Ki of 5.5 pM [112].
Furthermore, only one hydroxylic group is placed between the two catalytic aspartates, qual-
ifying KNI-272 as member of the first generation of HIVP inhibitors. Two water molecules
can be observed in the crystal structure: W301 and W607. W301 is the “flap water”, and
W607 is in close vicinity to one of the catalytic aspartates (with a distance of 3 Å). It forms
a hydrogen bond to the ligand’s hydroxylic group. We performed pKa calculations both
with and without W607 to probe its influence on the protonation states. The water molecule
W301 was not included explicitly due to its large distance from the catalytic dyad.
We explored the hydrogen-bond formation capability of the ligand’s hydroxylic group to
both aspartates by means of rotating the OH group in steps of 30 degrees (”rot-scan”). For
each step, a pKa calculation was performed. We observed dependencies on the calculated
pKa values: using εProtein = 20, the pKa value of one aspartate fluctuates within two log
units, and that of the second by one log unit. In the crystal structure, the distance of the
hydroxy oxygen amounts to 2.6 Å with respect to the carboxylate oxygen of the first aspar-
tate, whereas the distance to the second displays a value of 3.1 Å. For the pKa calculations
presented in Table 4.7 and 4.8, an orientation of the ligand OH group has been considered
which reveals the lowest pKa for the proximate aspartate (Asp25 labeled in the crystal struc-
ture): in this orientation, a hydrogen bond can be formed to this aspartate. This evidence
is in agreement with NMR experiment [26] where this aspartate forms two hydrogen bonds,
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one to W607, and a second to the ligand. The NMR experiment also revealed the pKa values
for the catalytic dyad; they were found to be < 2.5 and > 6.2 for the coupled system of the
two aspartates.
This is in agreement with the predictions based on semi-empirical quantum mechanical
calculations that the system of aspartates is in mono-protonated state once complexed with
KNI-272 [113]. In summary, all calculations suggest that the protease system remains in
the same mono-protonated state upon complexation of the ligand KNI-272.
A comparison of the results in Table 4.7 and 4.8 shows that the influence of the pres-
ence or absence of the water molecule W607 can modulate the pKa value of the proximal
aspartate by up to 0.5 log units. However, this has only minor impact on the resulting proto-
nation states and inventory. The influence of different orientations of the water molecule was
not probed, but it is assumed that the influence is of minor importance, because an ”ideal”
hydrogen bond between the W607 and Asp25 has been modelled for our calculations.
In Table 4.9, we compare our results with those of Trylska et al.; the experimentally de-
termined pKa values are also listed. The results are similar for Asp25’, whereas large
deviations are observed for Asp25. Suprisingly, opposing trends are suggested for both stud-
ies while decreasing εProtein from 20 to 4: in our case, the pKa value of Asp25 is increased,
whereas in the Trylska et al. study a decrease is suggested. Possibly in the latter study
(which uses different charge models for the different dielectric constants) the PARSE charges
show better performance for εProtein = 4. Best agreement to experiment is achieved with our
PEOE PB charges using εProtein = 20. Most importantly, all calculations suggest the overall
trend correctly: the catalytic dyad remains in the mono-protonated state.
S6
The hydroxyethylene sulfone S6 is another asymmetric inhibitor. The binding mode of its
hydroxylic group resembles the binding mode of the central hydroxylic group of KNI-272.
Inhibitor S6 has been developed in our group and binds with a Ki of 45 nM [114, 115].
Similar to the KNI-272 complex, S6 provokes different local environments next to the two
aspartates of the catalytic dyad. Interestingly, a water molecule close to one of the aspar-
tates is missing, although the S6 and KNI-272 structures are similar. No experimental data
regarding the protonation states of the catalytic aspartates are available.
As the crystal structure determination cannot eludicate the orientation of hydrogens, the












Table 4.7: pKa calculations on HIVP complexed with KNI-272 (1HPX).
apo (ligand-deleted from the complex) complexed with KNI-272
ε pKa1 H
+ a pKa2 H
+ a ΣH+ b pKa1 H
+ a pKa2 H
+ a ΣH+ b ∆ΣH+ c
(”aspartate1”) (”aspartate2”) (”aspartate1”) (”aspartate1”) ≈ ∆n
4 5.98 0.89 11.10 1.00 1.89 5.51 0.76 28.71 1.00 1.76 -0.13
10 3.78 0.06 7.24 0.99 1.05 3.84 0.06 13.43 1.00 1.06 +0.01
20 2.93 0.01 5.88 0.88 0.89 3.1 0.01 7.99 1.00 1.01 +0.12
anet degree of protonation of aspartate1 or aspartate2 at pH=5
bnet degree of protonation of the dyad at pH=5
cnet change of protonation upon ligand binding
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Table 4.8: pKa calculations on HIVP complexed with KNI-272 (1HPX), but considering one explicit water
molecule (W607) in the complexed form.
complexed with KNI-272
ε pKa1 H
+ a pKa2 H
+ a ΣH+ b ∆ΣH+ c
(”aspartate1”) (”aspartate2”) ≈ ∆n
4 5.20 0.61 29.63 1.00 1.61 -0.28
10 3.37 0.02 13.60 1.00 1.02 -0.03
20 2.71 0.01 7.98 1.00 1.01 +0.12
anet degree of protonation of aspartate1 or aspartate2 at pH=5
bnet degree of protonation of the dyad at pH=5
cnet change of protonation upon ligand binding
Table 4.9: Comparison with results from Trylska et al. [52] and experimentally determined pKa values.
HIVP complexed with KNI-272
PEOE PB Trylska et al. NMR [26]
pKa1 H
+a pKa2 H
+ a pKa1 H
+ a pKa2 H
+ a pKa1 pKa2
(”aspartate1”) (”aspartate2”) (”aspartate2”) (”aspartate2”)
ε = 4 5.20 0.61 29.63 1.00 1.9 0.00 27.0 1.00 < 2.5 > 6.2
ε = 20 2.71 0.01 7.98 1.00 4.5 0.26 7.0 0.99 < 2.5 > 6.2
anet degree of protonation of aspartate1 or aspartate2 at pH=5
aspartates are close enough to form a hydrogen bond); the distance of the carboxylic oxygen
amounts to 2.52 Å to the first aspartate and 2.61 Å to the second. Accordingly, we also per-
formed a ”rot-scan” of this ligand OH-group in steps of 30 degrees to detect the dependence
of the pKa values on the orientation of the OH group. For the results shown in Table 4.10,
we selected an orientation in which the ligand’s hydroxylic group forms a hydrogen bond to
the proximal aspartate.
A comparison with the results from KNI-272 shows that the pKa value of the aspartate
which is hydrogen-bonded to the ligand’s hydroxylic group is much lower for the S6/HIVP
complex. Most likely this is due to the shorter distance between the oxygen atoms of the
hydrogen-bond in the S6 complex (2.52 Å) compared to the KNI-272 complex (2.96 Å).
The pKa values resulting from our calculations must be seen in the light of the relative
shifts. Hence, we can assume that a conserved mono-protonated state of the catalytic dyad












Table 4.10: pKa calculations on HIVP complexed with S6 (1XL5).
apo (ligand-deleted) complexed with S6
ε pKa1 H
+ a pKa2 H
+ a ΣH+ b pKa1 H
+ a pKa2 H
+ a ΣH+ b ∆ΣH+ c
(”aspartate1”) (”aspartate2”) (”aspartate1”) (”aspartate2”) ≈ ∆n
4 4.05 0.10 11.95 1.00 1.10 -0.52 0.00 31.10 1.00 1.00 -0.10
10 2.13 0.00 7.24 0.99 0.99 0.53 0.00 15.20 1.00 1.00 +0.01
20 1.93 0.00 5.77 0.85 0.85 1.08 0.00 8.45 1.00 1.00 +0.15
anet degree of protonation of aspartate1 or aspartate2 at pH=5
bnet degree of protonation of the dyad at pH=5
cnet change of protonation upon ligand binding
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VX-478
In the design of S6, VX-478 (now on the market and named amprenavir), was taken as a
parent scaffold [114, 115] bearing a similar central hydroxyl group. It binds with a Ki of




2, respectively) pockets in a
similar way as S6.
Analogous to the study of KNI-272 and S6, we performed a ”rot-scan” of the central
ligand hydroxylic group to detect its optimal orientation. Regardless of the orientation, the
catalytic dyad is in the mono-protonated state. We chose the orientation which revealed
the lowest pKa value for the deprotonated aspartate. Similar to the complexes with KNI-
272 and S6, we can assume that the catalytic dyad remains mono-protonated upon ligand
binding.
S7
The ligand S7 is another HIVP inhibitor that was developed in our group. It bears a pyrro-
lidine ring as new central core [114, 115]. The (R,R)-enantiomer of S7 binds with a Ki of 1.5
µM [114, 115], which makes it a weaker inhibitor than the other compounds studied in this
contribution. One interesting structural feature is a water molecule, which is located in close
vicinity of one of the two aspartates. The position of this water molecule is almost identical
with the position of the water molecule W607 in the KNI-272 complex.
The experimentally determined pKa value for unsubstituted pyrrolidine amounts to 11.3
[117]; we assigned a pKa value of 11 for our calculations. We studied the charge setting for
the neutral form of the pyrrolidine: either the charge of one of the bonded hydrogens was
set to zero, or both hydrogens were ”equally neutralized” (the charge settings are shown in
Figure 4.4). The second model considers to some degree a possible dynamic fluctuation of the
remaining hydrogen between the two orientations to the neighboring aspartates. However,
both charge models produce similar pKa predictions, and the results in Table 4.12 and 4.13
correspond to the ”equally neutralized”-model. The results suggest very low pKa values for
both aspartates. The large pKa difference between the two aspartates can be explained by
the asymmetric position adapted by the pyrrolidine ring. It approaches one of the aspartates
0.3 Å closer than the other. This aspartate reveals the lower pKa value. In contrast, as
expected for a strong salt bridge, the pKa of the ligand nitrogen increases compared to the
unbound state.












Table 4.11: pKa calculations on HIVP complexed with VX-478 (1HPV).
apo (ligand-deleted) complexed with VX-478
ε pKa1 H
+ a pKa2 H
+ a ΣH+ b pKa1 H
+ a pKa2 H
+ a ΣH+ b ∆ΣH+ c
(”aspartate1”) (”aspartate2”) (”aspartate1”) (”aspartate1”) ≈ ∆n
4 5.07 0.54 11.36 1.00 1.54 3.84 0.06 26.89 1.00 1.06 -0.48
10 3.45 0.03 7.29 0.99 1.02 2.71 0.01 12.52 1.00 1.01 -0.01
20 2.88 0.01 5.94 0.90 0.91 2.49 0.00 7.52 1.00 1.00 +0.09
anet degree of protonation of aspartate1 or aspartate2 at pH=5
bnet degree of protonation of the dyad at pH=5












Table 4.12: pKa calculations on HIVP complexed with S7 (1XL2). The model pKa of the unbound S7 is 11.0.
apo (ligand-deleted) complexed with S7
ε pKa1 H
+ a pKa2 H
+ a ΣH+ b pKa1 H
+ a pKa2 H
+ a ΣH+ b ∆ΣH+ c
(”aspartate1”) (”aspartate2”) (”aspartate1”) (”aspartate1”) ≈ ∆n
4 5.40 0.72 10.48 1.00 1.72 27.38 -21.0 0.00 -4.55 0.00 0.00 -1.72
10 3.54 0.03 7.23 0.99 1.02 19.59 -9.60 0.00 -1.00 0.00 0.00 -1.02
20 2.92 0.01 5.97 0.90 0.91 16.66 -4.18 0.00 0.42 0.00 0.00 -0.91
anet degree of protonation of aspartate1 or aspartate2 at pH=5
bnet degree of protonation of the dyad at pH=5













































Figure 4.4: Charge settings for the neutral and charged states of the ligand S7. The model ”equally neutral-
ized” is displayed on the top right, whereas the charges for explicit deletion of one hydrogen are given
in the bottom right corner. The difference in the net charge for both neutral charge models is caused
by the differing number of atoms. ”q” corresponds to the sum of the labeled charges.
Table 4.13: pKa calculations on HIVP complexed with S7, where one explicit water molecule next to the
more acidic aspartate has been considered (in contrast to the results in Table 4.12).
complexed with 7
ε pKa1 H
+ a pKa2 H
+ a ΣH+ b ∆ΣH+ c
(”aspartate1”) (”aspartate2”) ≈ ∆n
4 -21.00 0.00 -4.93 0.00 0.00 -1.72
10 -11.13 0.00 -1.17 0.00 0.00 -1.02
20 -4.85 0.00 0.32 0.00 0.00 -0.91
anet degree of protonation of aspartate1 or aspartate2 at pH=5
bnet degree of protonation of the dyad at pH=5
cnet change of protonation upon ligand binding
studied, and the results show a decreased pKa value for the neighboring aspartate (labeled
Asp25, see Table 4.13), which forms a hydrogen bond to this water molecule. However, this
shift has no impact on the predicted protonation states.
Overall, the pKa values of the two aspartates are shifted to a pKa range where (at pH
= 5) the catalytic dyad is supposedly fully deprotonated and, thus, present with two nega-
tively charged carboxylate groups.
4.4 DISCUSSION 65
4.4 DISCUSSION
The two investigated apo crystal structures exhibit some deviations in the geometry, in
consequence the computed pKa values differ slightly. With increasing εProtein these differ-
ences decrease, an observation which correlates with a growing damping of the electrostatic
interactions. For this reason larger εProtein values have been recommended as they better
consider possible relaxations or local conformational multiplicity of the protein [18]. This
might serve as an explanation why in general the values obtained with εProtein = 4 deviate
rather strongly from experiment. Furthermore, site-site interactions are responsible for the
increased pKa value of one of the catalytic aspartates in the apo structure. Possibly such
site-site interactions are overestimated with εProtein = 4, as too extreme pKa values are
predicted. Likely, again the electrostatic interactions on short distance are exaggerated.
The initial goal for this contribution was to benchmark our PEOE PB charges, particu-
larly to estimate changes of protonation states upon ligand binding. Experiments reveal the
catalytic dyad to be mono-protonated for the uncomplexed enzyme. In case of the study
of Trylska et al. [52], this is only predicted using a εProtein = 4. With our methodology,
reasonable values are obtained with a setting of εProtein = 10 or 20 for both apo structures.
The use of different charge models provides a probable explanation for these differences.
As mentioned, the geometrical differences of the two apo structures result in somewhat
deviating assignments of pKa values. Nevertheless, the relative differences are similarly
predicted. This observation points to a crucial aspect: What is the most reasonable approxi-
mation of the uncomplexed geometry, or, vice versa, by how much does the uncertainty in the
reference geometry effect the accuracy of the computed pKa calculations? It can be argued
that a ligand-deleted structure of the protease is only a very approximate represensation of
the actual apo geometry, however, it is straightforward to produce. We want to compare
Table 4.14: Comparison of mean pKa values for the real apo structures and the ligand-deleted HIVP structures
pKaexp mean pKaapo mean pKaligand−deleted
ε = 4 ε = 10 ε = 20 ε = 4 ε = 10 ε = 20
pKa1 3.1-3.7 5.45 3.77 3.12 5.26 3.33 2.73
pKa2 4.9-6.5 9.79 6.79 5.69 11.02 7.24 5.90
the pKa values obtained using different structures as input. In Table 4.14, the mean pKa
values averaged across the five different ligand-deleted structures are summarized. Facing
them with the pKa values obtained for the two experimental protein structures reveals a
maximum deviation of 1.3 log units for εProtein = 4. Considering the more reasonable settings
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of εProtein = 10 or 20, the mean deviations reduce to 0.4 log units. As these deviations are
smaller than the consequences of modifying the εProtein settings, the use of a ligand-deleted
geometry appears a justifiable and very practical approximation for the intended calculations.
To predict the properties of the DMP-323 complex, εProtein = 10 seems to be optimal.
The twofold protonation of the catalytic dyad is predicted correctly. Also for the KNI-272
complex, εProtein = 10 produces the best results. Here the protonation state of the catalytic
dyad is estimated mono-protonated in agreement with experiment. A zero net uptake of
protons is correctly predicted. The placement of an explicit water close to the catalytic dyad
has only minor impact on the computed results.
The binding modes of S6 and VX-478 are rather similar, particularly with respect to
the central hydroxylic group. Nonetheless, the resulting pKa values of both aspartates reveal
different pKa values for the two complexes, particularly for εProtein = 4. Independent of the
actual values for εProtein, however, the catalytic dyad is predicted to adopt mono-protonation,
and zero uptake of protons is predicted upon complex formation.
The inhibitor S7 induces a protonation pattern of the catalytic dyad which deviates from
other complexes: both carboxy functions are predicted to be deprotonated. Although rather
negative (most likely exaggerated) pKa values are computed for both catalytic aspartates
the release of one proton upon complex formation is predicted, particularly for a setting of
εProtein = 10 or 20.
A central hydroxy group is present in the three ligands KNI-272, S6 and VX-478. Experi-
mental evidence (by means of NMR measurements [26]) about the orientation of this hydroxy
group is only available for the KNI-272 complex. We explored different orientations of the
hydroxy group by systematically scanning all rotamers. The hydrogen bond formation takes
influence on the pKa values of the catalytic dyad, as fluctuations of one to two pKa units are
observed. We selected the orientation that achieves the lowest pKa value of all rotamers in
agreement with experimental evidence.
4.5 CONCLUSIONS
Inhibitor binding to HIVP can induce a change of protonation of the two catalytic aspar-
tates, as confirmed experimentally. We performed pKa calculations on five different HIVP
complexes and two apo structures. Depending on the type of ligand, different protonation
states for the catalytic dyad are predicted. In cases where experimentally determined pKa
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values are available our results have been compared to these reference values. Furthermore,
a similar theoretical study [52] has been consulted for comparison. For the apo form of
HIVP, the mono-protonated state of the catalytic dyad is evidenced by kinetic measurements
[25, 24]. Our calculations suggest very similar results either based on the geometry of two
apo structures or of five complex structures from which the ligand has been removed. This
fact underlines that the straightforward strategy of deleting the ligand from the complex
structure is sufficiently accurate to produce relevant pKa calculations (in case of HIVP).
The binding of KNI-272 to HIVP involves no change of protonation of the catalytic dyad.
The pKa calculation correctly reproduces this experimental result. In contrast, upon bind-
ing of DMP-323 one proton is picked-up by the catalytic dyad. Also, this experimentally
observed change is correctly reproduced by our calculations.
In the second part of the study, we have predicted protonation states of the catalytic
dyad for three HIVP complexes where no experimental data on the protonation states are
available. For the complexes with one central ligand hydroxyl group facing the dyad (S6,
VX-478), the mono-protonated state is suggested. Most interestingly, for the S7 complex
with a formal positive charge on the central ligand’s pyrrolidine moiety interacting with the
dyad, both aspartates are predicted to occur in the deprotonated state. To the best of our
knowledge, this protonation pattern has not yet been suggested or experimentally observed
for any HIVP complex.
Knowledge about the most likely protonation state of ligands and protein residues is an
important prerequisite to correctly setup computational drug design techniques such as
docking and virtual screening. Possibly deviating settings can retrieve alternative hits since
the assigned physicochemical properties (e.g. with respect to hydrogen-bond donor or ac-
ceptor functionalities) of the catalytic aspartates determine what type of ligand functional
groups will be accepted as potential binder of the protease. Furthermore, with respect to
ITC experiments the present calculations can indicate whether superimposed changes of
protonation might affect the measured heat signal. In case of overlaid protonation steps
elaborate corrections have to be performed to obtain the net heat of binding which allows
together with the recorded binding constant to factorize the binding affinity into entalpic
and entropic contributions.
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5 PROTONATION EFFECTS IN HUMAN
ALDOSE REDUCTASE
5.1 INTRODUCTION
Aldose reductase (AR) is a NADPH-dependent oxidoreductase [118] catalyzing the reduc-
tion of a wide variety of carbonyl compounds to the corresponding alcohols. Human aldose
reductase (hAR) consists of a single polypeptide chain of 315 residues with a molecular mass
of 35.8 kDA [119] (see Figure 5.1). The active site of hAR is segmented into two parts: the
anion pocket composed by the residues Asp43, Tyr48, Lys77 and His110 and the hydrophobic
specificity pocket flanked by the residues Trp111, Thr113, Leu300 and Cys303. The enzy-
matic reaction catalyzed by hAR involves, subsequently to the reductive hydride transition,
a proton transfer. It is postulated that either Tyr48 [120] or His110 [121] are engaged in this
process. This unresolved question makes hAR an attractive test case for our pKa calculation
methodology.
Although the physiological role of hAR in healthy individuals is still unclear, the enzyme is
believed to be of primary importance in the development of severe degenerative complications
of diabetes mellitus [122]. Therefore, hAR represents a putative target for the treatment of
this disease. In general, two inhibitor classes exist for the inhibition of hAR: compounds
with a carboxylic head group and spiro-hydatoins. Both classes bind similarily to the anion
binding pocket, but differ substantially with respect to the specificity pocket: if the ligand
bears appropriate hydrophobic parts, the specificity pocket opens up, otherwise it remains
in closed state (see Figure 5.2).
In an extensive experimental study [23], we performed a full thermodynamic and crys-
tallographic characterization of the hAR/ligand binding process. In the context of this
study, we were able to detect protonation changes occuring in due course of the complexation
process. The ligands used for our investigation are shown in Figure 5.3. In this contribution
we try to collect evidence for the structural interpretation of the detected protonation effects
by means of pKa calculations. In two previous studies on protein-ligand complexes where
protonation transfer steps have been recorded experimentally [111, 123], we were able to com-
pute atypical protonation states which explained the change in the protonation inventory. In
this context, atypical protonation means a non-standard protonation, i.e. a protonated acid
or a deprotonated base.
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Figure 5.1: Crystal structure of hAR adapts a TIM-barrel fold (eight-stranded α-β fold). The cofactor,
the ligand IDD388 and the anion pocket are given in stick representation. (a) Overall view of the
structural elements. (b) Hydrogen bonds formed by the carboxylic head group of the ligand towards
Tyr48 and His110.
Figure 5.2: Complexes of human aldose reductase with the inhibitors (a) IDD388 (b) Fidarestat. Tyr48
and His110 are shown in stick representation (see Figure 5.3). The specificity pocket (lower part) is
closed in the complex with Fidarestat, whereas it opens up when IDD388 is bound.
5.2 RESULTS
5.2.1 Calculations for five holo structures
We used five ligand-deleted structures of hAR (from the studied complexes) to investigate the
conformational influence on the resulting pKa values. The analysis of ligand-deleted struc-


































Figure 5.3: Chemical formulae of the aldose reductase inhibitors used in this investigation.
by simply removing the ligand from the complex. One apo structure has recently become
available [124], but as the bound cofactor is missing in the active site, this structure is not
of relevance for our studies. We explored the following different settings in our calculations
on the holo enzyme:
• Usage of different values for the dielectric constant (10 or 20).
• Impact of the orientation of the Tyr48 OH group on its pKa value.
• Oxidation state of the cofactor: oxidized (NADP+) or reduced (NADPH).
The findings with respect to the different applied settings will help to accomplish the most
appropiate parameter adjustment. All results are listed in Tables 5.1 and 5.2. The two con-
sidered orientations of the Tyr48 OH group are shown in Figure 5.4. It appeared reasonable
to us to place the OH-group in different orientations, since such a group is known to adopt
different conformational states.
In case of His110, Nδ has been defined as sole titratable group. In the complexes to be
simulated in the following, Nε will be permanently involved in a hydrogen bond to the lig-
ands. For consistency in our calculations, we only considered Nδ as titratable group also












Table 5.1: Variation of the Tyr48 pKa depending on the orientation of the Tyr48 OH group: oriented either towards Asp43 or His110 (see Figure 5.4). The cofactor
is given in the oxidized and reduced state, as well.
ligand-deleted AR 1
ε cofactor ”IDD388” ”IDD393” ”BTB” ”Fidarestat” ”Sorbinil” mean (std dev)
10Asp43 NADP
+ 5.82 6.27 6.79 7.14 7.10 6.62 (0.51)
10Asp43 NADPH 11.45 11.32 11.53 11.60 11.32 11.44 (0.11)
10His110 NADP
+ 8.45 8.52 9.09 8.90 9.02 8.80 (0.26)
10His110 NADPH 13.94 13.80 14.40 13.44 13.29 13.77 (0.39)
20Asp43 NADP
+ 7.70 7.84 8.15 8.19 8.23 8.02 (0.21)
20Asp43 NADPH 10.98 11.05 11.15 11.60 11.32 11.22 (0.22)
20His110 NADP
+ 8.72 8.78 9.13 8.97 9.08 8.94 (0.16)












Table 5.2: Variation of the His110 pKa depending on the orientation of the Tyr48 OH-group: oriented either towards Asp43 or His110 (see Figure 5.4). The cofactor
is given in the oxidized and reduced state, as well.
ligand-deleted AR
ε cofactor ”IDD388” ”IDD393” ”BTB” ”Fidarestat” ”Sorbinil” mean (std dev)
10Asp43 NADP
+ -1.40 -1.70 -1.47 -0.91 -1.03 -1.30 (0.29)
10Asp43 NADPH 0.09 -1.70 -1.47 -0.91 -1.03 0.27 (0.31)
10His110 NADP
+ -1.75 -2.02 -1.80 -1.19 -1.36 -1.62 (0.30)
10His110 NADPH -0.59 -2.02 -1.80 -1.19 -1.36 -0.50 (0.51)
20Asp43 NADP
+ 2.34 2.07 2.36 2.44 2.46 2.33 (0.14)
20Asp43 NADPH 3.67 2.07 2.36 2.44 2.46 3.71 (0.21)
20His110 NADP
+ 1.97 1.78 2.02 2.17 2.15 2.02 (0.14)
20His110 NADPH 3.18 1.78 2.02 2.17 2.15 3.25 (0.19)
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Figure 5.4: The two studied orientations of the Tyr48 OH group: it is either oriented towards Asp43 or
His110/ligand. For better orientation, the carboxylic head group of IDD388 is shown on the left hand
side.
in the uncomplexes situation. For the two remaining titratable residues of the active site
(Asp43, Lys77), no pKa values indicating an atypical protonation state are observed and,
hence, they are not listed in the Table.
For Tyr48, it is observed that the oxidation state of the cofactor has an eminent influ-
ence on the pKa value; in general, the consideration of NADP+ instead of NADPH results in
mean pKa values lowered by 3-5 log units. All calculations with the reduced cofactor suggest
a fully protonated tyrosine, which is not the case considering the oxidized cofactor. This
behaviour may serve as a first indicator that Tyr48 is deprotonated in the holo enzyme. The
influence of εProtein is opposing for the different forms of the cofactor: the mean Tyr48 pKa
value is reduced when NADP+ is bound and a lower εProtein is applied, whereas it increases
when NADPH is present. The adopted orientation of the OH-group takes a remarkable
influence (a further indicator for the perturbed protonation state of Tyr48). For xylanase,
we were able to show the influence of the Tyr-OH orientation on the pKa value of an active
site glutamate [85]. Choosing an orientation towards Asp43 (εProtein = 10, NADP
+) gives a
mean pKa value of 6.62 which corresponds to a protonation degree of 4 %. For His110, very
low pKa values are calculated in all cases (negative values for a dielectric constant of 10).
The oxidation state of the cofactor shows no influence on an altered protonation state of the
histidine residue. Hence, all shifts fall into a range suggesting that this residue remains in
neutral state and is not involved in any changes.
74 5.2 RESULTS
5.2.2 Calculations for compounds with carboxylic head groups
The structures of hAR complexed with IDD388, IDD393 and BTB have been crystal-
lographically determined in-house. ITC revealed a proton uptake of the protein-ligand
complexes from the buffer of +0.8± 0.2 (IDD388, BTB) or +0.9± 0.2 (IDD393) moles of
protons. The results for the different cofactor oxidation states are given in Table 5.3. They
suggest that the carboxylic group of the ligand should remain deprotonated (neglecting the
NADPH/εProtein = 10 calcualtion). Furthermore, the calculations propose (definite proto-
nation states of the two crucial residues: Tyr48 appears in the protonated form. For the
calculations with NADPH, a partially protonated His110 is suggested for the BTB complex
with εProtein = 20, whereas it is fully deprotonated for the NADP
+ calculations.
Our calculations on the holo structures showed (see previous section) that the protona-
tion degree of Tyr48 before ligand binding amounts to 4 % (Tyr48 OH group orientation
towards Asp43, εProtein = 10, NADP
+). Using these settings, a ∆ncalc of +0.96 is obtained
for all three complexes. This in excellent agreement with experiment.
ITC experiments with IDD388 and NADPH instead of NADP+ gave a ∆n of +0.2 ± 0.04.
In the NADPH calculations for the holo structure, the results suggest a fully protonated
Tyr48. The calculations for the IDD388 complex reveal that the Tyr48 pKa is increased.
Taken together with the partially protonated His110 (εProtein = 20), this gives a ∆ncalc
of 0.09 which matches remarkably with the experiment. Aslo the setting to εProtein = 10
suggest neglectable change in protonation which correctly predicts the trends seen in the
experiments. For the sake of completeness, the results for the two other complexes are also
given in Table 5.3.
5.2.3 Calculations for compounds containing spiro-hydatoins
Spiro-hydatoins belong to the second class of inhibitors studied in this contribution. They
bind with a cyclic hydantoin moiety in a similar region of the binding pocket as the carboxylic
head group of the carboxylic acid type inhibitors. The experimentally determined pKa values
(in aqueous solution) for Fidarestat and Sorbinil are 7.9 [125] and 8.7 [126]: these pKa
values fall very close to the applied pH conditions and make these inhitors sensitive to pka
shifts resulting in protonation changes.
ITC experiments indeed revealed ∆n to be +0.3 ± 0.1 for Fidarestat and +0.1 ± 0.02












Table 5.3: Computed pKa values for Tyr48 and His110 for complexes of hAR with three inhibitors (IDD388, IDD393, BTB). The cofactor is given in the oxidized
and reduced state, as well. ∆ncalc: change in protonation upon ligand binding with respect to the holo form. The ligand pKa values are not considered for any
protonation change (cf. NADPH/εProtein = 10.
IDD388 IDD393 BTB
pKa pKa pKa pKa pKa pKa pKa pKa pKa ∆ncalc
ε cofactor (COO) (Tyr48) (His110) (COO) (Tyr48) (His110) (COO) (Tyr48) (His110)
10 NADP+ -5.54 16.15 1.92 -2.79 17.16 1.61 -3.78 31.10 2.54 +0.96
10 NADPH 0.36 31.10 5.24 6.28 31.10 -3.03 8.48 31.10 -1.85 ±0.0
20 NADP+ -2.32 13.67 5.48 -1.04 14.37 5.14 -1.90 16.33 5.60 +0.51
20 NADPH -0.55 22.25 7.02 0.64 22.11 6.90 1.79 23.72 7.29 +0.09/+0.07/+0.16
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from our calculations on the respective complexes are summarized in Table 5.4. The trend
observed for the pKa’s of Tyr48 and His110 is similar to the trend seen in the previous
section, whereas the pKa values of the ligands are only modulated by less than one log unit.
Since this pKa shift is too small to be regarded as significant, we do not give any ∆ncalc
values for the respective cases.
ITC experiments with NADPH instead of NADP+ gave a ∆n of −0.3±0.05 (Fidarestat) and
∆n of −0.5± 0.2 (Sorbinil). Our calculations estimate a protonated tyrosine residue in the
holo state with the reduced cofactor. Therefore, the experimentally detected change in the
protonation inventory must result from the titratable group of the ligand. Our calculations
can not predict this. Finally, we explored the influence of the formal charge distribution on
the proton inventory. The computational details are given in the Materials and Methods
section. The changed settings result in lower pKa values of the ligand (see Table 5.5), but
these values are still not sufficient to predict ligand binding in the deprotonated state.
5.3 DISCUSSION
5.3.1 Holo structures
The ITC experiments together with results from mutagenesis give clear evidence that Tyr48
adopts a deprotonated state in the complex with the oxidized cofactor prior to ligand bind-
ing - this was confirmed by measurements for the Tyr48Phe mutant which revealed a ∆n
of 0.0 for the IDD388 complex [23]. We obtain a (median) pKa value of 6.62 for Tyr48
(OH oriented towards Asp43, εProtein = 10, NADP
+) which corresponds to an almost fully
deprotonated tyrosine residue.
The orientation of the OH-group of Tyr48 shows remarkable influence on its pKa value
(see Table 5.1). We postulate that two different orientations for the Tyr48 OH-group might
exist: before ligand binding, it points towards Asp43, and after complexation it orients
towards the ligand and His110 (see Figure 5.4). A similar case was reported in a recent
PB-based pKa study on an alcohol dehydrogenase, for which the binding pocket exhibits
(amongst others) a lysine, tyrosine and NAD+. Multiple orientations of the Tyr OH-group
were extensively investigated and a significant influence on its pKa value has been registered
[127]. One other issue concerns the structural situation prior to ligand binding: since no holo
structure is available, we can only speculate about the preferred OH orientation in the active













Table 5.4: Computed pKa values for Tyr48, His110 and the ligand for two complexes (Sorbinil, Fidarestat.) The cofactor is given in the oxidized and reduced state,
as well.
Fidarestat Sorbinil
pKa pKa pKa pKa pKa
ε cofactor (Ligand) (Tyr48) (His110) (Ligand) (Tyr48) (His110)
10 NADP+ 8.56 28.71 -6.24 8.37 29.87 -5.68
10 NADPH 12.22 31.10 -4.27 10.87 31.10 -3.85
20 NADP+ 7.70 14.52 0.59 8.45 16.61 0.96
20 NADPH 9.77 21.96 1.67 23.03 18.54 2.00
78 5.3 DISCUSSION
Table 5.5: Computed pKa values for Fidarestat/hAR using different formal charge models. For further
explanations on the different models see Figure 5.6. The cofactor is in the oxidized form.
model ε pKa







According to kinetic studies, the pKa value of Tyr48 is 8.25 in the binary NADP+/aldose
reductase complex [120]. In a theoretical study by Várnai and Warshel [128], who used the
protein-dipole Langevin-dipole method, the pKa of Tyr48 was estimated to be ∼ 8.5 in the
holo structure with the cofactor in the oxidized form. For the NADPH/aldose reductase
complex, the experimentally determined pKa value is 8.7 [120]. We obtain a mean value
of about 11 (εProtein = 10) or 13 (εProtein = 20), see Table 5.1. Possibly our calculations
overestimate the upward pKa shift of Tyr48, but the correct trend is predicted.
For the ligand-deleted IDD388 structure, variation of the initial settings were examined: (a)
explicit consideration of one water molecule which donates a hydrogen-bond from beyond the
catalytic site to the Nδ atom of His110, (b) titration of the Nε atom of His110 instead of the
Nδ atom (see above). The effect of the explicit consideration of an additional water molecule
is rather marginal - the resulting impact is less than 0.1 pKa units on the pKa of Tyr48. On
the other hand, variation of the titratable nitrogen of His110 results in pKa values for Tyr48
which deviate by 0.5 log units (predicting a higher pKa value for Tyr48 compared to the Nδ
titration).
Analyzing the different effects that determine the calculated pKa value of Lys77 which
is suggested to to exhibit a pKa beyond > 14 in most calculations shows the following: the
intrinsic pKa value neglecting the influence of the local neighborhood reveals a pKa of 5
(ε = 10) or 8 (ε = 20), however, the site-site interactions with Asp43 and Tyr48 induce a
strongly shifted pKa value of this residue. In contrast, the intrinsic pKa value of Tyr48 is
about 10, but the site-site interactions with Lys77 and His110 reduce its pKa value. This
also supports the assumption of a deprotonated state of Tyr48 and illustrate the complex
nature of the binding pocket.
Former studies have speculated that His110 serves as proton acceptor in the catalytic mech-
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anism of aldose reductase [121]. In none of our calculations we collect evidence for such a
doubly protonated state of the imidazole moiety (see results for the complexes) and a recent
neutron diffraction study of complex with a bound carbonic acid-type inhibitor clearly shows
His110 in the neutral state [129].
5.3.2 Carboxylic head groups
Our calculations support the assumption that Tyr48 is protonated and His110 is deprotonated
upon ligand binding, the large absolute values and extreme shifts should only by interpreted
as an indicator for the induced trends.
• For an εProtein = 10, the calculations suggest an unreasonably high Tyr48 pKa value.
Some aspects have to be considered as possible explanation for these extreme and
exaggerated values. In the previously studied systems, we maximally encountered three
titratable groups in close vicinity, and a straightforward explanation was possible [111,
123]. Here in the present case we have to consider five titratable sites and thus the
locally crowded charged groups make the handling of such a system rather complex.
For example, Tyr48 and Lys77 form a coupled system in the studied hAR complexes:
both possess close intrinsic pKa values and they interact with the titratable groups of
the ligand through short distance.
• The agreement to experiment for the IDD393 complex with the reduced cofactor seems
only fairly convincing (∆n = +0.09). However, we regard the experimentally recorced
protonation effect of ∆n = +0.2 ± 0.04 as rather small to be quantitatively correctly
predictable by our pKa calculations methodology. But it is notable that the correct
trend is predicted.
5.3.3 Spiro-hydatoins
The ITC measurements discussed so far strongly suggest that Tyr48 is deprotonated in the
oxidized holo enzyme [23] and gets protonated upon ligand binding (IDD388, IDD393,
BTB). Complexing hAR with ligands possessing a spiro-hydatoin moiety transfers a basic
function into the active site. Due to their pKa of about 8-9 in solution they will be par-
tially protonated and most likely they release their proton upon complexation to Tyr48.
Indeed, ITC supports such a scenario: For Fidarestat, the experiment detected an uptake
of ∆n = +0.3 ± 0.1 moles of protons for wild type, whereas the Tyr48Phe mutant shows a
release of ∆n = −0.5 ± 0.1. The latter experiment shows that, besides Tyr48, the ligand’s
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cyclic hydantoin functionality is involved in the change of the protonation inventory. For
Sorbinil, ∆n was measured to be +0.1 ± 0.02. This difference compared to Fidarestat is
explained by the higher pKa value of the latter ligand in aqueous solution (8.7 [126] instead
of 7.9 [125]). For both spiro-hydatoins, the results from ITC can be explained by assuming
a fully deprotonated ligand once bound to hAR.
Our calculations are not in line with this experimental finding, because two issues become
apparent:
• Only marginal pKa shifts are observed for the ligand upon binding, however, as they
fall very close to the pH of the buffer, small changes would provoke strong changes in
the protonation inventory. The modulation of the formal charge distribution according
to the different models does not take significant impact. Furthermore, the solvation
contribution of the ligands leads to intrinsic pKa values higher than the model pKa,
and the site-site interactions further shift the pKa to higher values. Obviously, the
computational approach does not favor the deprotonated state of the hydantoin.
• The formation of doubly (ligand/Tyr48) or triply (ligand/Tyr48/Lys77) coupled sys-
tems with close pKa values depending on the predefined εProtein results in a very com-
plex system and complicates an accurate assignment of pKa values.
What can we learn from this disagreement? Conclusive answers are difficult to find and
we therefore want to consult some structural evidences (see Figure 5.5): An inspection of
the binding pocket in the bound state suggests that the deprotonated ligand is favorably
stabilized by hydrogen bonds to His110 and Tyr48. These two residues supposedly interact
strongly with the ligand, which is also reflected by the strong contributions from the site-site
interactions. Possibly, this mutually polarizing system is further stabilized and these effects
are not captured by our calculations.
5.4 CONCLUSIONS
In this contribution, we attempted to identify residues involved in a proton transfer observed
experimentally by ITC in aldose reductase [23]. We postulate that the active site residue
Tyr48 is deprotonated in the holo structure with oxidized cofactor but neutral in the situation
with reduced NADPH. Examples have been reported in literature, where a deprotonated
tyrosine occurs in the active site:
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Figure 5.5: Network of H-bonds form by the spiro-hydatoin moiety of Sorbinil and Fidarestat.
• For two members of the short-chain dehydrogenase/reductase family, namely dehy-
dratase and epimerase, kinetic measurements for an active site tyrosine residue reveal
pKa values of 6.41 (dehydratase) [5] and 6.08 (epimerase) [6]. In both enzymes, the cru-
cial tyrosine is neighbored by a lysine residue and the cofactor NAD+. Both are made
responsible for stabilizing the deprotonated tyrosine. In case of the epimerase, it was
even possible to experimentally determine the contributions fostering the more acidic
pKa value: approximately 3 units come from the positive electrostatic field contribution
generated by NAD+ and the neighbored lysine residue, whereas the hydrogen-bonding
to a serine residue contributes about 0.6 units [6].
The structural similiarity of our hAR case with the latter epimerase/dehydratase examples
underlines that a deprotonated tyrosine is likely given in holo hAR.
ITC revealed that protons are picked-up, most likely by Tyr48, upon binding of ligands
with carboxylic head groups (IDD388, IDD393, BTB). We were able to provide evidence
for this interpretation as a large pKa shift for Tyr48 is observed. In the case of Fidarestat
and Sorbinil, the ITC experiment proved that the ligands bind in the deprotonated state.
Our calculations propose pKa values for the bound ligand close to the pH of the buffer thus
at least partial protonation would have to be assumed. Possibly, this insufficient accuracy
results from short-comings of our computational approach which is not capable to correctly
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cope with strong polarization effects and the complexity of a coupled protonation system of
three adjacent groups with close pKa values.
5.5 MATERIALS AND METHODS
We used the following (publically available) crystal structure of complexed hAR: 1PWM
(Fidarestat). In-house structures were evaluated for the hAR complexes of Sorbinil,
IDD388, IDD393 and BTB. The 2D structures of the ligands are shown in Figure 5.3.
For Fidarestat and Sorbinil, the experimentally determined pKa values are 7.9 [125] and
8.7 [126]. The experimentally determined pKa value of IDD594 is 2.9 [130]. The structural
similarity to the ligands IDD388 and IDD393 tempted us to perform the pKa calculations
with a pKa value of 3.0 for the carboxylic head group. For the sake of consistency, a pKa
value of 3.0 was also assumed for the ligand BTB. However, changing the pKa value to 2.0
or 4.0 does not suggest an altered proton inventory.
We used different models to distribute the formal charge in Fidarestat, because the negative
formal charge of the deprotonated state is, at least partially, reallocated over the hydatoin
ring: with our PEOE PB algorithm, it is only possible to deal with one such possible re-
allocation (this is shown in Fiure 5.6a). All details on the settings, including the resulting
atomic partial charges, are given in Figure 5.6.
For the pKa calculations, we applied the same methodology as recently described else-
where [85]. MEAD was employed as PB solver [64], whereas we performed calculations with
a dielectric constant of 20 and 10, in parallel, to demonstrate its influence. REDUCE was
used to generate hydrogens for the residues of the protein [75]. For the calculations of the
complexes, the orientation of the Tyr48 OH group was chosen to point towards the ligand.
SYBYL was applied to add hydrogens to the cofactor and the ligands [101]. To study the
protonation effects upon ligand binding, two pKa calculations are required: One without
ligand and a second with the bound ligand. Only the titratable residues within a 12 Å
sphere around the active site were selected for evaluation of the site-site interactions in order
to reduce the computational effort (in total, there are 91 titratable residues in hAR). This
results in the following 26 titratable residues: Lys21, Asp43, Cys44, His46, Tyr48, Glu51,
Lys77, Cys80, Tyr82, His83, His110, Lys116, Lys119, Glu120, Glu185, Cys186, Tyr209,
Asp216, Lys262, Cys298, Cys303, His306, Lys307, Asp308, Tyr309, His312. We used the
higher populated conformer for amino acids in case a split conformation has been assigned
to in the crystal structure.

































































Figure 5.6: Atomic partial charges for the neutral and charged form of Fidarestat. Three different variants
have been applied for the deprotonated state: (a) The acidic nitrogen atom is assigned to an initial
formal charge of -1.0. (b) Both ring nitrogens are assigned initially to a formal charge of -0.5. (c) Each
ring atom bears an initial formal charge of -0.2.
In contrast to our standard settings for the titration of histidine residues, the Nδ atom
of His110 was titrated (see Results section).
For (doubly or triply) coupled systems, we superimposed the titration curves and derived
the pKa values from the intersections at, e.g. pKa2.5/pKa1.5/pKa0.5.
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6 PDB2PQR AS A NEW TOOL FOR THE
SETUP OF PKA CALCULATIONS ON
PROTEIN-LIGAND COMPLEXES
6.1 INTRODUCTION
The setup of pKa calculations in a fairly straight-forward manner of protein-ligand complexes
has become feasible on the basis of our PEOE PB charges [85]. Their applications shows
convincing agreement to experimental data for a series of complexes [111, 123]. However,
the current setup still requires an elaborate procedure especially for the handling of the
titratable groups of a ligand. Furthermore, all previous calculations have been performed
using the PBE (Poisson-Boltzmann equation) solver MEAD [64], which is no longer main-
tained and supported: this fact puts further development in question. To circumvent these
issues, we decided to combine our algorithm for the PEOE PB charge assignment into within
the framework of PDB2PQR [27] and we extend it to the automated handling of ligands.
PDB2PQR is a convenient tool for the generation of PQR files, which serve as input for the
PBE solver APBS [131]; the PQR file contains charges and radii for all protein atoms.
The workflow for setting up a pKa calculation with PDB2PQR is shown schematically
in Figure 6.1. Generally, it is sufficient to submit a PDB file for the protein and a MOL2
file for the ligand, and all necessary steps are conveniently performed by PDB2PQR without
interference of the user. The organization of this technically oriented report is as follows: in
section 6.2, the general workflow will be presented. This description will be instructive for
the interested non-expert to gain insights into the concept of PDB2PQR. In the subsequent
section 6.3, a detailed characterization of the involved scripts is given, which is of main
relevance for developers.
6.2 PDB2PQR PRINCIPLES
PDB2PQR is a Python (version 2.3.5, www.python.org) based command line tool, which
is controlled via various flags. The standard invocation (addition of optimized hydrogen
positions to a protein structure and a debumping of missing atoms) is as follows:
pdb2pqr.py --ff=charmm --apbs-input 2LZT.pdb 2LZT_H.pdb
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Figure 6.1: Workflow for the setup of pKa calculations for a protein-ligand complex with PDB2PQR.
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The --ff=charmm flag switches to the CHARMM22 [77] parameters for the protein, other
available parameter sets are AMBER99 [132] and PARSE [65]. The option --apbs-input
generates an input file for a calculation with APBS. Other optional switches are --nodebump
and --noopt, which suppress the debumping and hydrogen position optimization, respec-
tively.
For the preparation of an input suitable for pKa calculations, the Python script pka.py
has been written by Jens Erik Nielsen, and we included the extensive ligand processing. The
script pka.py is invoked as follows:
pka.py --ff=peoepb --lig test.mol2 test.pdb
Basically, pka.py creates all PDB2PQR objects for the ligand (the details are given in section
6.3) and makes a full flexible treatment of the ligand possible within pka.py. The PEOE PB
charges are assigned in the beginning, and a substructure search for the detection of titratable
groups follows. The substructure matching is necessary, since no general rule exists of how
to detect the titratable groups of a ligand and to derive the corresponding model pKa values.
For this purpose, a database (http://polymerase.ucd.ie/pka lig tool) was created [133] in
which structural data for molecules with experimentally determined pKa values (in aqueous
solution) are stored. Two possibilities exist for the deposition of data:
• via the graphical online front end: it can be accessed by a web browser, the data is
entered to the system by an appropiate interface on a web page, and the required 3D
structure is uploaded as MOL2 file.
This procedure represents a convenient way for populating the database, although it
can be not done in a high-throughput manner.
• via a Python script (molpka.py): it uses 2D MDL MOL files as input, the program
CORINA [71] converts these structures into 3D MOL2 files, and the necessary entries
can be entered interactively.
At first glance, this procedure seems rather tedious, but displays its strength when
processing large quantities of structural data.
The basis for the experimental data is built by a pKa compilation
(http://research.chem.pse.edu/brpgroup/pKa compilation.pdf). In the current version, there
are ca. 350 entries in the database covering a large variety of different chemical structures.
After a successful matching, the query molecule from the database is converted into a
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PDB2PQR object. Then, pka.py assembles all settings necessary for the titration of the
ligand (model pKa value, atom(s) being protonated/deprotonated, type of titratable group)
together with the protein settings. In a final step, the input file for APBS is generated.
6.3 SCRIPTS
All routines called from pka.py for the ligand processing are given in a schematic workflow
shown in Figure 6.2. In the top part of this figure, all scripts added and modified in the course
Figure 6.2: Routines called by pka.py. All scripts added and modified for the ligand extension are given in the
grey box in the top right corner. Only protein-specific definitions are set in step (3), no modifications
have been done here and, thus, it is not annotated in the top of this figure.
of this project are listed. The invoked routines are commented in the following enumeration
(the numbering corresponds to the indices in Figure 6.2):
1. In the first step, the parsing of the ligand MOL2 file is initiated. The MOL2MOLECULE
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class has been added to the pdb module to implement MOL2 parsing. Furthermore,
the HETATM class has been modified in the pdb module. The different objects created
for the ligand by PDB2PQR are shown in Figure 6.3.
Furthermore, the ligand parsing process includes the charge assignment procedure
(peoe PDB2PQR).
2. The MOL2 parsing is completed after the ligand object has inherited all attributes from
the get ligand topology class, which belongs to the NEWligand topology module.
3. Amino acid and rotamer definions are set by myDefintion which calls the definitions
module. However, no such information is available for the ligand and, thus, the corre-
sponding classes are set empty. Accordingly, no modification were done in this module.
4. Finally, the substructure matching is called within pka.py by the routine find titratable groups.
This function itself uses a shared object for the clique detection algorithm (Algorithms.so),
see Section 6.3.1 for further details.
The library of molecules with experimentally determined pKa values is deposited in
the module trial templates. An examplary entry of this module is given in Figure
6.4.





Figure 6.4: Examplary entry of the module trial templates containing the query molecules for substructure
matching..
6.3.1 Substructure matching
The substructure search is based on a graph alignment algorithm implemented in our group
[134], it is a routine written in C++ and can be called as shared object from Python. The
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Bron-Kerbosch-Algorithm forms the methodological basis of the substructure matching: it
detects the maximum common subgraph by finding the maximum clique of a graph [135] (see
Figure 6.5). Prior to the substructure search, the ligand and query molecules are converted
Figure 6.5: Simple example of the graph alignment algorithm detecting the maximum common subgraph.
The ligand (I) and the the query molecule (II) are given as molecules and the corresponding graphs.
The association graph of the two graphs is given in the lower part of this Figure. In the present (trivial)
case, the maximum clique is formed by the complete association graph. The graph (III) represents the
maximum common substructure, which is reported to PDB2PQR.
into an association graph, which forms a suitable basis for the clique detection. When the sub-
structure matching is performed, we look for the maximum common substructure/subgraph:
this means that a match is only reported if the whole query fragment is found in the ligand.
6.3.2 pka lig tool
The database pka lig tool containing structural data for molecules with experimentally
determined pKa values is written in MySQL (version 4.1.16, www.mysql.com). It was initated
by the cooperation with Jens-Erik Nielsen and maintained by Chresten Søndergaard. The
organization is given in Figure 6.6. Four different tables have been created in which the data
is organized:
• the ligands table: it covers the structural data of the ligand such as the MOL2 file,
xyz file (for the JMOL visualisation on the web page), an optional smiles code, ID and
name for the ligand
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Figure 6.6: Organization of the database pka lig tool containing experimentally determined pKa values (in
aqueous solution) of small organic molecules.
• the atoms table: it contains atomic entries such as name, ID and MOL2 type and the
ID of the ligand
• the pdb source table: if ligand data originates from a protein-ligand complex, the
corresponding PDB code is deposited here
• the pka values table: the experimental values are stored here plus annotations such
as literature references, solvent, temperature etc.
The content of the database can be converted to a format suitable for the substructure




Recent hardware development increase the computing power, in consequence many biolog-
ical and chemical processes can now be successfully modelled in a way which was not to
imagine 20 years ago. Examples of such processes are molecular dynamics studies of large
biomolecules, the prediction of free energy of binding for protein-ligand complexes, investiga-
tions of reaction paths in enzymes, to mention only a few. One issue which is still unresolved
concerns the accurate estimation of protonation states in protein-ligand complexes.
In this thesis, we present the development of a novel charge assignment procedure named
PEOE PB (Partial Equalisation of Orbital Electronegativities - optimized for Poisson-
Boltzmann calculations), which represents a method for the assignment of atomic partial
charges. It works reliably with both proteins and small organic molecules using a consistent
approach. Such charges are a key parameter in Poisson-Boltzmann (PB) calculations, which
are a well-established method for pKa calculations of proteins. The development of the
PEOE PB charges is necessary, because no generic procedure exists to perform PB-based
pKa calculations of protein-ligand complexes. The development of the PEOE PB charges is
described in section 2.
We adapted the PEOE formalism to optimally predict solvation free energies of small organic
molecules. Modifications were performed in a heuristic manner, i.e. purely result-oriented.
The changes considered exclusively parameter a of the PEOE polynomial (see section 2.2.1).
In our optimization protocol, we first attempted to reproduce best solvation free energies
of the polar amino acids (r2 is 0.94, RMSD is 0.84) and continued with a dataset of 80
small organic molecules (r2 is 0.78, RMSD is 1.57). The latter step underlines the generic
character of our PEOE PB charges. Subsequently, we performed calculations on a dataset of
nine (apo) proteins with 132 experimentally determined pKa values and obtained an overall
RMSD of 0.88. The dielectric constant of the protein is set to 20. Active site residues with
highly shifted pKa values are given for two enzymes of the dataset. For these, the following
issues were indicated:
• The value of the dielectric constant has to be lowered from 20 to 4, which can be
partially explained by the degree of burial of the binding pocket.
• The orientation of the tyrosine OH group was observed to have a remarkable influence
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on the pKa value of an active site residue (a glutamate with a highly increased pKa
value). This fact emphasizes that the position of polar hydrogens can be crucial.
In the final step of our PEOE PB validation study, we performed pKa calculations for three
protein-ligand complexes, where experiment revealed a proton transfer. All our calculations
agree with the experimental findings.
In section 3, we describe pKa calculations for a series of ligands binding to the serine
proteases trypsin and thrombin. For the studied complexes, we previously performed an
extensive ITC and crystallographic study and were able to identify protonation changes for
four complexes [22]. However, since ITC measures only the overall proton exchange, it does
not provide structural insights into the functional groups involved in the proton transfer.
By using Poisson-Boltzmann calculations based on our PEOE PB charges, we compute pKa
values for all complexes from our previous work in order to reveal the residues with altered
protonation states. The results indicate that His57, a member of the catalytic triad, is
responsible for the most relevant pKa shifts resulting in the experimentally detected proto-
nation changes. This finding is in contrast to our previous assumption that the observed
protonation changes occur at the carboxylic group of the ligands. The newly detected proton
acceptor is used for a revised factorization of the ITC data, which is necessary in cases where
the protonation inventory changes upon complexation. pKa values of complexes showing no
change of protonation in the ITC experiment are reliably predicted in most cases, whereas
predictions of strongly coupled systems remain problematic. Such coupled systems appear if
two (or more) strongly interacting titratable groups are close to each other.
The HIV protease (HIVP) is a prominent example of successful structure-based drug
design, and it is a well-studied system for which, as experimental evidence shows, protona-
tion changes in the active site occur upon ligand binding (section 4). In the apo enzyme,
the catalytic dyad consisting of two aspartates is in the mono-protonated state. This proto-
nation state can be altered by ligands bearing a cyclic urea moiety. Our PEOE PB charge
model reliably suggests the experimentally determined protonation states in the active site
of HIVP. Furthermore, we perform pKa calculations for two HIVP complexes with novel
types of inhibitors developed and synthesized in our group [115, 114]. For these complexes,
no experimental knowledge on the protonation states is given. For one of the compounds,
containing a central pyrrolidine ring, the calculations predict that both catalytic aspartates
should be deprotonated upon ligand binding (Table 4.12 and 4.13). Such a protonation
pattern has yet not been observed in any HIVP complex.
Similarly to the experimental trypsin/thrombin study, a combined crystallographic and
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thermodynamic investigation of the ligand complexation process of human aldose reduc-
tase (hAR) was performed in our group [23]. The ITC measurements detected a proton
transfer induced by the ligand binding process. Our calculations suggest an active site ty-
rosine residue (Tyr48) as proton acceptor, which is equivalent to a deprotonated tyrosine
in the holo enzyme. This is in agreement with the ITC results for the Tyr48Phe mutant.
Good quantitative agreement with the ITC experiment is obtained for the hAR complexes
with inhibitors bearing a carboxylic head group. In contrast, the calculations cannot reliably
predict the properties of inhibitors with a cyclic hydantoin moiety. A possible explanation
for the deficiency is the fact that the ligand shows a strong electrostatic interaction with the
active site tyrosine and lysine residues. Furthermore, its pKa value in aqueous solutions falls
next tothe physiological pH range which makes the system very sensitive to the actual pKa
shifts.
One limiting factor for the large-scale application of the pKa calculation methodology pre-
sented here concerns the ligand processing. For this purpose, we included the PEOE PB
algorithm in the PDB2PQR program. This tool serves as the input file generator for the
Poisson-Boltzmann solver APBS. Besides the fully flexible ligand consideration within the
PDB2PQR framework, substructure matching has been enabled for the ligand. With this
technique, it is possible to automatically detect titratable groups of the ligand and assign pKa
values. These pKa values originate from a database which has designed built and currently
contains 348 molecules with experimentally determined pKa values.
7.2 Zusammenfassung
Die ständige Weiterentwicklung der Computer-Hardware und die daraus resultierende Steige-
rung der Rechenleistung ermöglicht heutzutage eine erfolgreiche Modellierung von chemis-
chen und biologischen Prozessen, die vor 20 Jahren noch undenkbar war. Als Beispiele sind
Molekulardynamik-Simulationen grosser Biomoleküle, die Berechnung freier Bindungsen-
ergien von Protein-Ligand-Komplexen oder auch Untersuchungen von Reaktionswegen in
Enzymen zu nennen. In einem Bereich mangelt es jedoch weiterhin an akkuraten Methoden:
die Abschätzung von Protonierungszuständen in Protein-Ligand-Komplexen.
In der vorliegenden Arbeit zeigen wir die Entwicklung einer neuen Methode der Ladungszu-
weisung, genannt PEOE PB (Partial Equalisation of Orbital Electronegativities - optimiert
für Poisson-Boltzmann Rechnungen). Diese Methode stellt eine konsistente Ladungszuweisung
sowohl für Proteine als auch für kleine organische Moleküle dar. Die Ladungen sind entschei-
dende Parameter bei Poisson-Boltzmann (PB)- Rechnungen. PB-Rechnungen stellen eine
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etablierte Methode bei der Bestimmung von pKa-Werten in Proteinen dar. Die Entwicklung
von PEOE PB-Ladungen ist notwendig geworden, da es keine generische Methode gibt, PB-
basierte pKa-Berechnungen in Protein-Ligand-Komplexen durchzuführen.
Der PEOE-Ansatz wurde gewählt, um zunächst die freien Solvatationsenergien kleiner or-
ganischer Moleküle bestmöglich vorherzusagen. Modifikationen wurden heuristisch, d.h.
ergebnisorientiert vorgenommen, wobei Änderungen lediglich den Parameter a des PEOE-
Polynoms betreffen. Bei unserer Optimierung versuchten wir zunächst, die experimentell
bestimmten freien Solvatationsenergien polarer Aminosäuren (r2 = 0.94, RMSD = 0.84) und
anschließend eines Datensatzes von 80 kleinen organischen Molekülen (r2 = 0.78, RMSD =
1.57) zu reproduzieren. Die Verwendung des letztgenannten Datensatzes zeigt den gener-
ischen Charakter unserer PEOE PB-Ladungen. Abschliessend führten wir Rechnungen an
einem Datensatz von neun (apo-)Proteinen mit 132 experimentell bestimmten pKa-Werten
durch und erzielten einen RMSD von 0.88. Die Dielektrizitätskonstante im Protein war
hierbei auf 20 gesetzt. Aminosäurereste in Bindetaschen mit stark verschobenen pKa-Werten
lagen bei zwei Enzymen des Datensatzes vor, in diesen Fällen wurden folgende Beobachtungen
gemacht:
• Die Dielektrizitätskonstante musste von 20 auf 4 gesenkt werden, was teilweise durch
die Vergrabenheit der Bindetasche erklärt werden kann.
• Die Orientierung der Hydroxylgruppe des Tyrosins hatte einen beachtlichen Einfluss
auf den pKa-Wert eines Aminosäurerestes in der Bindetasche (ein Glutamat mit stark
erhöhtem pKa-Wert). Diese Tatsache unterstreicht den entscheidenden Einfluss der
Orientierung polarer Wasserstoffatome.
Im letzten Schritt unserer PEOE PB-Validierung führten wir pKa-Berechnungen für drei
Protein-Ligand-Komplexe (die im Experiment einen Protonentransfer zeigten) durch: in
allen Fällen stimmten unsere Berechnungen mit dem Experiment überein.
In einer folgenden reinen Anwendungsstudie führten wir pKa-Rechnungen für eine Serie
von Liganden, die an die Serin-Proteasen Trypsin und Thrombin binden, durch. Für
diese Komplexe waren bereits ausführliche ITC- und Kristallographie-Studien gemacht wor-
den, und für vier dieser Komplexe konnten Änderungen in den Protonierungszuständen
detektiert werden [22]. Da ITC-Experimente jedoch nur gesamtheitliche Änderungen in der
Protonierung messen, konnten diese Experimente keinen Aufschluss darüber geben, welche
funktionellen Gruppen tatsächlich am Protonentransfer beteiligt sind. Um diese Gruppen
identifizieren zu können, führten wir PB-Rechnungen, basierend auf unseren PEOE PB-
Ladungen, durch. Die resultierenden pKa-Werte zeigen, dass His57 (einer der drei katalytisch
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aktiven Reste) für die wichtigsten pKa-Änderungen, die sich im Experiment als Änderungen
im Protonierungszustand zeigen, verantwortlich ist. Dies steht im Widerspruch zu unserer
früheren Annahme, dass die Änderungen im Protonierugszustand an der Carboxylgruppe der
Liganden stattfinden. Der neuentdeckte Protonenakzeptor wurde für die Refaktorisierung
der ITC-Daten eingesetzt; dies ist wichtig für Fälle, in denen sich die Protonierung während
der Komplexbildung ändert. Die pKa-Werte von Komplexen, die im ITC-Experiment keine
Änderung im Protonierungszustand zeigen, werden in den meisten Fällen verlässlich vorherge-
sagt, während dies in Fällen stark koppelnder Systeme schwierig bleibt. Solche Fälle treten
auf, wenn zwei (oder mehr) interagierende titrierbare Gruppen räumlich nahe beiander liegen.
Die HIV-Protease (HIVP) ist ein bekanntes Beispiel für erfolgreiches strukturbasiertes
Wirkstoffdesign und stellt ein gut untersuchtes System dar, bei dem Änderungen des Pro-
tonierungszustandes während der Ligandenbindung auftreten, wie im Experiment gezeigt
wurde. Das System der HIVP stellt einen Ausgangspunkt für eine weitere Anwendungsstudie
unserer PEOE PB-Ladungen dar. Bei dem Apo-Enzym befindet sich die zwei katalytisch
aktiven Reste (Aspartate) im monoprotonierten Zustand. Dieser kann sich ändern, wenn
Liganden binden, die eine zyklische Harnstoff-Gruppe enthalten. Unser PEOE PB-Modell
reproduziert den experimentell bestimmten Protonierungszustand. Ferner führten wir pKa-
Berechnungen für zwei HIVP-Komplexe mit neuartigen Inhibitoren, die unserer Gruppe
entwickelt und synthetisiert wurden [115, 114], durch. In diesen Fällen gibt es keiner-
lei experimentelle Daten für die Protonierungszustände. Einer der Inhibitoren enthält ein
Pyrrolidin-Ring: hier sagten die Berechnungen voraus, dass beide katalytisch aktiven As-
partate nach Ligandenbindung deprotoniert vorliegen. Solch ein Protonierungsmuster wurde
bisher in keinem HIVP-Komplex beobachtet, weder experimentell noch mittels einer Berech-
nungsmethode.
Neben den experimentellen Trypsin/Thrombin-Studien wurden auch kombinierte kristal-
lographische und thermodynamische Untersuchungen der Ligandenbindung an humaner
Aldose-Reduktase (hAR) in unserer Gruppe vorgenommen [23]. Die ITC-Messungen
zeigten einen durch die Ligandenbindung induzierten Protonentransfer. Unsere pKa-Rech-
nungen lassen darauf schließen, dass ein Tyrosin-Rest der Bindetasche (Tyr48) als Protone-
nakzeptor fungiert, was bedeutet, dass das Tyrosin im Holo-Enzym deprotoniert vorliegt.
Dies stimmt mit den Ergebnissen von ITC-Messungen an Tyr48Phe-Mutanten überein.
Während bei hAR-Komplexen von Inhibitoren mit einer Carboxyl-Kopfgruppe die Rech-
nungen gut im Einklang mit den ITC-Experimenten standen, zeigten sich Ungenauigkeiten
bei der Vorhersage von Inhibitoren mit einer zyklischen Hydantoin-Gruppe. Eine mögliche
Erklärung hierfür ist die starke elektrostatische Wechselwirkung zwischen Ligand und den
Tyrosin bzw. Lysin-Resten der Bindetasche. Ferner liegen die pKa-Werte in wässriger Lösung
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nahe dem physiologischen pH-Bereich, was das System sehr anfällig für kleine Änderungen
des pKa-Wertes macht.
Ein limitierender Faktor für die breite Anwendung unserer PEOE PB Ladungsmethode
bei pKa-Rechnungen stellt die vorangehende Prozessierung der Liganden dar. Zu diesem
Zweck implementierten wir den PEOE PB-Algorithmus in das PDB2PQR-Programm (dieses
erzeugt Input-Dateien für das PB-Programm APBS). Liganden wurden in der PDB2PQR-
Umgebung als voll flexibel betrachtet und es wurde eine Suchprozedur für gemeinsame
Substrukturen eingeführt. Mit dieser Technik ist es möglich, titrierbare Gruppen des Ligan-
den automatisch zu erkennen und ihnen pKa-Werte zuzuweisen. Diese pKa-Werte stammen
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